<html lang="en" class="pb-page js" data-request-id="94d6e50f3229f214-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6e50f3229f214-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/K5XTnDj8rMSUON698F23APxM8fA9QNu4Rj-jeOaEhHLjzSQpYQYLFKUtokPpoH_1hgly2jr5kA1Q3ZKfjbT03A=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6e50f3229f214-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.8100003063368647"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Ophthalmology General|Diabetes">
<meta name="Specialties" content="Ophthalmology|Endocrinology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2204225","title":"Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema","category":"Research","type":"Original Article","topics":"Ophthalmology General|Diabetes","specialties":"Ophthalmology|Endocrinology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-08-25T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Ophthalmology General|Diabetes\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Ophthalmology|Endocrinology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2204225","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema","doi":"10.1056/NEJMdo006644","issueDate":"2022-08-25T00:00Z","age":"6Months-1990","isFree":"n","topics":"Ophthalmology General|Diabetes","viewType":"Full","specialties":"Ophthalmology|Endocrinology"},{"type":"Quick Take","title":"Aflibercept or Bevacizumab First for Diabetic Macular Edema","doi":"10.1056/NEJMdo006643","issueDate":"2022-08-25T00:00Z","age":"6Months-1990","isFree":"n","topics":"Ophthalmology General|Diabetes","viewType":"Full","specialties":"Ophthalmology|Endocrinology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6e50f3229f214-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema"><meta name="dc.Creator" content="Chirag D. Jhaveri"><meta name="dc.Creator" content="Adam R. Glassman"><meta name="dc.Creator" content="Frederick L. FerrisIII"><meta name="dc.Creator" content="Danni Liu"><meta name="dc.Creator" content="Maureen G. Maguire"><meta name="dc.Creator" content="John B. Allen"><meta name="dc.Creator" content="Carl W. Baker"><meta name="dc.Creator" content="David Browning"><meta name="dc.Creator" content="Matthew A. Cunningham"><meta name="dc.Creator" content="Scott M. Friedman"><meta name="dc.Creator" content="Lee M. Jampol"><meta name="dc.Creator" content="Dennis M. Marcus"><meta name="dc.Creator" content="Daniel F. Martin"><meta name="dc.Creator" content="Carin M. Preston"><meta name="dc.Creator" content="Cynthia R. Stockdale"><meta name="dc.Creator" content="Jennifer K. Sun"><meta name="dc.Description" content="In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not imp..."><meta name="Description" content="In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not imp..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-08-25"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2204225"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202208253870806"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2208454"><meta name="dc.Relation" content="YXQYoa2204225"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2204225">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2204225">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2204225">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema | NEJM">
        <meta property="og:title" content="Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2204225">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/ca35ae30-b18e-47c3-ac0e-73859ef16b4d/nejmoa2204225_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/ca35ae30-b18e-47c3-ac0e-73859ef16b4d/nejmoa2204225_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="In eyes with diabetic macular edema, the relative efficacy of administering aflibercept
monotherapy as compared with bevacizumab first with a switch to aflibercept if the
eye condition does not imp...">
        <meta name="twitter:description" content="In eyes with diabetic macular edema, the relative efficacy of administering aflibercept
monotherapy as compared with bevacizumab first with a switch to aflibercept if the
eye condition does not imp...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2204225">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2204225">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;issue:issue:doi\:10.1056/nejm_2022.387.issue-8;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2204225;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2204225" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2204225" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2204225" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2204225" class="inputDoi"><input type="hidden" value="C.D. Jhaveri and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:692-703" class="inputCitation"><input type="hidden" value="07-14-2022" class="inputEPubDate"><input type="hidden" value="August 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6e50f3229f214-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Chirag D.</span> <span property="familyName">Jhaveri</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adam R.</span> <span property="familyName">Glassman</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Frederick L.</span> <span property="familyName">Ferris</span> III, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Danni</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.S.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maureen G.</span> <span property="familyName">Maguire</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">John B.</span> <span property="familyName">Allen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carl W.</span> <span property="familyName">Baker</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+9</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Browning</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Matthew A.</span> <span property="familyName">Cunningham</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Scott M.</span> <span property="familyName">Friedman</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lee M.</span> <span property="familyName">Jampol</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dennis M.</span> <span property="familyName">Marcus</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel F.</span> <span property="familyName">Martin</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carin M.</span> <span property="familyName">Preston</span>, <span property="honorificSuffix">M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cynthia R.</span> <span property="familyName">Stockdale</span>, <span property="honorificSuffix">M.S.P.H.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Jennifer K.</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the DRCR Retina Network<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-9</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">July 14, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">692</span>-<span property="pageEnd">703</span></div><div class="doi">DOI: 10.1056/NEJMoa2204225</div><div class="core-enumeration"><a href="/toc/nejm/387/8"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">8</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DChirag%2BD.%2BJhaveri%252C%2BAdam%2BR.%2BGlassman%252C%2BFrederick%2BL.%2BFerris%2BIII%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D8%26contentID%3D10.1056%252FNEJMoa2204225%26title%3DAflibercept%2BMonotherapy%2Bor%2BBevacizumab%2BFirst%2Bfor%2BDiabetic%2BMacular%2BEdema%26publicationDate%3D08%252F25%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2204225" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DChirag%2BD.%2BJhaveri%252C%2BAdam%2BR.%2BGlassman%252C%2BFrederick%2BL.%2BFerris%2BIII%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D8%26contentID%3D10.1056%252FNEJMoa2204225%26title%3DAflibercept%2BMonotherapy%2Bor%2BBevacizumab%2BFirst%2Bfor%2BDiabetic%2BMacular%2BEdema%26publicationDate%3D08%252F25%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/42b1ff29-6a87-40e6-9247-b8db389ed89e/nejmoa2204225.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2204225.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204225" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2204225" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2204225.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is unclear.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">At 54 clinical sites, we randomly assigned eyes in adults who had diabetic macular edema involving the macular center and a visual-acuity letter score of 24 to 69 (on a scale from 0 to 100, with higher scores indicating better visual acuity; Snellen equivalent, 20/320 to 20/50) to receive either 2.0 mg of intravitreous aflibercept or 1.25 mg of intravitreous bevacizumab. The drug was administered at randomization and thereafter according to the prespecified retreatment protocol. Beginning at 12 weeks, eyes in the bevacizumab-first group were switched to aflibercept therapy if protocol-specified criteria were met. The primary outcome was the mean change in visual acuity over the 2-year trial period. Retinal central subfield thickness and visual acuity at 2 years and safety were also assessed.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f0.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/ca35ae30-b18e-47c3-ac0e-73859ef16b4d/assets/images/large/nejmoa2204225_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 312 eyes (in 270 adults) underwent randomization; 158 eyes were assigned to receive aflibercept monotherapy and 154 to receive bevacizumab first. Over the 2-year period, 70% of the eyes in the bevacizumab-first group were switched to aflibercept therapy. The mean improvement in visual acuity was 15.0 letters in the aflibercept-monotherapy group and 14.0 letters in the bevacizumab-first group (adjusted difference, 0.8 letters; 95% confidence interval, −0.9 to 2.5; P=0.37). At 2 years, the mean changes in visual acuity and retinal central subfield thickness were similar in the two groups. Serious adverse events (in 52% of the patients in the aflibercept-monotherapy group and in 36% of those in the bevacizumab-first group) and hospitalizations for adverse events (in 48% and 32%, respectively) were more common in the aflibercept-monotherapy group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this trial of treatment of moderate vision loss due to diabetic macular edema involving the center of the macula, we found no evidence of a significant difference in visual outcomes over a 2-year period between aflibercept monotherapy and treatment with bevacizumab first with a switch to aflibercept in the case of suboptimal response. (Funded by the National Institutes of Health; Protocol AC ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03321513" target="_blank">NCT03321513</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006643/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/8c2c421b-43fc-4894-aee9-a3a503942a97/media/NEJMdo006643_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006643/full/" class="ng-do-media_item-title-link">Aflibercept or Bevacizumab First for Diabetic Macular Edema</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 15s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Diabetic macular edema is a leading cause of vision loss in working-age adults.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> Current standard treatment for diabetic macular edema involves intravitreous injections of anti–vascular endothelial growth factor (anti-VEGF) agents into the eye.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup> Aflibercept and ranibizumab have been approved by the Food and Drug Administration (FDA) for the treatment of diabetic macular edema, and bevacizumab, a lower-cost alternative, is used off-label.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4" href-manipulated="true">3,4</a></sup></div><div role="paragraph">These three drugs are effective in improving visual acuity.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-1" href-manipulated="true" aria-label="Reference 5">5</a></sup> Although a comparative-effectiveness trial of these drugs showed similar outcomes in eyes with a baseline visual acuity of 20/40 or better,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-2" href-manipulated="true" aria-label="Reference 5">5</a></sup> aflibercept treatment resulted in better vision than bevacizumab therapy at 2 years in eyes with a baseline visual acuity of 20/50 or worse (mean improvement, 18.1 letters with aflibercept vs. 13.3 letters with bevacizumab) and better vision through 1 year than ranibizumab therapy.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-3" href-manipulated="true" aria-label="Reference 5">5</a></sup> Nevertheless, many eyes with baseline vision of 20/50 or worse in the bevacizumab group had good vision outcomes, with 68% having a final visual acuity of 20/40 or better at 2 years.</div><div role="paragraph">Because the costs of aflibercept and ranibizumab are substantially higher than that of bevacizumab, an increasing number of insurers require step therapy, in which bevacizumab is used for the initial treatment with a switch to another anti-VEGF agent if the clinical response is unsatisfactory.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup> For eyes with a baseline visual acuity of 20/50 or worse, it is unclear whether this strategy compromises long-term visual acuity relative to aflibercept monotherapy. We conducted a randomized clinical trial to compare two strategies for treating diabetic macular edema involving the center of the macula in eyes with visual impairment (20/50 or worse): aflibercept monotherapy or bevacizumab first plus a switch to aflibercept therapy if the response was suboptimal.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Conduct and Oversight</h3><div role="paragraph">We conducted Protocol AC, a multicenter, randomized clinical trial at 54 clinical sites in the United States. The second, fourth, and fifth authors vouch for the accuracy and completeness of the data, and the first and third authors vouch for the fidelity of the trial to the <a href="#ap1">protocol</a> (available with the full text of this article at NEJM.org). The Jaeb Center for Health Research has confidentiality agreements with the authors or their institutions. The DRCR Retina Network had complete control over the design of the protocol, ownership of the data, all editorial content of presentations and publications related to the protocol, and the decision to submit the manuscript for publication.</div><div role="paragraph">The trial adhered to the principles of the Declaration of Helsinki and was approved by a central ethics board. All the patients provided written informed consent. An independent data and safety monitoring committee provided oversight. We followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines.</div></section><section id="sec-1-2"><h3>Trial Population</h3><div role="paragraph">Eligible patients were at least 18 years of age and had type 1 or 2 diabetes, at least one eye with a best-corrected Electronic Early Treatment Diabetic Retinopathy Study visual-acuity letter score of 24 to 69 (on a scale from 0 to 100, with higher scores indicating better visual acuity; Snellen equivalent, 20/320 to 20/50), center-involved diabetic macular edema on ophthalmoscopic examination, and central subfield thickness values greater than machine- and sex-specific thresholds on optical coherence tomography (OCT).<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-1" href-manipulated="true">7,8</a></sup> Eyes that had received anti-VEGF treatment for diabetic macular edema in the previous 12 months or any treatment for diabetic macular edema within the previous 4 months were excluded.</div></section><section id="sec-1-3"><h3>Trial Design</h3><div role="paragraph">Randomization schedules were generated with the use of a permuted block design (random block sizes of two or four), with stratification according to site. Patients with one study eye (i.e., with one eye involved in the trial) were randomly assigned in a 1:1 ratio to receive either 2.0 mg of intravitreous aflibercept (Eylea; the aflibercept-monotherapy group) or 1.25 mg of intravitreous bevacizumab (Avastin) with a switch to 2.0 mg of aflibercept if the eye met protocol criteria (bevacizumab-first group). For patients with two study eyes (i.e., with both eyes involved in the trial), the eye with the greater visual-acuity letter score was randomly assigned to a treatment group and then the other eye was assigned to the alternative treatment.</div><div role="paragraph">Visits occurred at baseline, every 4 weeks through 1 year, and then every 4 to 16 weeks in year 2 depending on disease progression and retreatment. Visual acuity with refraction and OCT scans were obtained by certified technicians at each visit. Fundus photographs were obtained annually, and assessment according to the Diabetic Retinopathy Severity Scale was performed by a reading center. Severity levels include 12 discrete steps ranging from 10 to 85, with higher levels indicating greater severity.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-1" href-manipulated="true" aria-label="Reference 9">9</a></sup> The patients were unaware of the treatment assignments at clinic visits but could become aware of the assigned trial group because of information on billing documents. Technicians at the annual visits, graders at the central reading center, and the medical monitor were unaware of the treatment assignments. The trial investigators were aware of the treatment assignments. Adverse events were coded according to the <i>Medical Dictionary for Regulatory Activities</i>, versions 20.0, 21.0, 22.0, 23.0, and 25.0.</div></section><section id="sec-1-4"><h3>Treatment Protocol</h3><div role="paragraph">Eyes were treated at randomization and thereafter according to the prespecified retreatment protocol (Fig. S2 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). Initially, six monthly injections were administered, unless the protocol-defined criteria for success and sustained stability were both met. (Success was defined as visual acuity of 20/20 or better and a central subfield thickness less than the sex- and device-specific threshold, and sustained stability was defined as no improvement or worsening in visual acuity or central subfield thickness over two consecutive injections.) The thresholds were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and 305 μm and 290 μm, respectively, on the Cirrus device (Zeiss). Starting at 24 weeks, the injection was deferred if there was sustained stability alone on the basis of real-time data entry by the clinical site for these measures. (An automated algorithm provided treatment instructions.) Injections were resumed if visual acuity or central subfield thickness worsened.</div><div role="paragraph">Beginning at 12 weeks, eyes in the bevacizumab-first group were switched to aflibercept therapy if the following criteria were met: persistent center-involved diabetic macular edema (defined as the central subfield thickness being above the eligibility threshold), an adequately treated eye (administration of bevacizumab injections at the previous two consecutive visits), no recent improvement in eye condition (no improvement of visual acuity by ≥5 letters and no decrease in central subfield thickness of ≥10% as compared with each of the two preceding visits or between each of the two preceding visits), and suboptimal vision (visual acuity, 20/50 or worse before 24 weeks or 20/32 or worse at 24 weeks or later) (<a href="#t1">Table 1</a>). Eyes that were switched to aflibercept therapy received two aflibercept injections, separated by 1 month, and then received aflibercept injections according to the retreatment protocol.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t1.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/e6156d2a-9bca-4687-9ba3-e01b8848776f/assets/images/large/nejmoa2204225_t1.jpg" height="1050" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Criterion</th><th class="xxxx-borders">Definition</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging01 shading">Persistent center-involved diabetic macular edema</td><td class="xxxx-borders hanging01 shading">Central subfield thickness on OCT greater than sex- and device-specific thresholds<a href="#t1fn2" role="doc-noteref">†</a></td></tr><tr data-type="row"><td class="xxxx-borders hanging01">Recent treatment of eye</td><td class="xxxx-borders hanging01">Receipt of injection with bevacizumab at the last two trial visits</td></tr><tr data-type="row"><td class="xxxx-borders hanging01 shading">No recent improvement in eye condition</td><td class="xxxx-borders hanging01 shading">Visual-acuity letter score not improved by ≥5 letters and central subfield thickness on OCT not improved by ≥10% as compared with each of the two preceding visits or between each of the two preceding visits</td></tr><tr data-type="row"><td class="xxxx-borders hanging01">Suboptimal vision</td><td class="xxxx-borders hanging01">Approximate Snellen score of 20/50 or worse (≤68 letters) before 24 wk or 20/32 or worse (≤78 letters) at 24 wk or later</td></tr></tbody></table></div><figcaption><div class="caption">Criteria for Switch to Aflibercept Therapy at 12 Weeks or Later.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">All four criteria had to be met for eyes to be switched from receiving bevacizumab first to receiving aflibercept therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The thresholds on optical coherence tomography (OCT) were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively, on the Cirrus device (Zeiss).</div></div></div></figcaption></figure></div></section><section id="sec-1-5"><h3>Trial Outcomes</h3><div role="paragraph">The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up. Secondary outcomes included the percentage of eyes in the bevacizumab-first group that met the switching criteria and the numbers of trial visits and trial injections completed during the 2-year trial period. Additional secondary outcomes included changes in visual acuity, central subfield thickness, retinal volume, and diabetic retinopathy severity, as well as visual-acuity threshold levels and diabetic retinopathy events. Safety outcomes included prespecified ocular and systemic adverse events.</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">We calculated that a sample of 312 eyes would be required in order for the trial to have approximately 90% power to detect a difference between groups, assuming a true difference of at least 3.5 letters in the mean change in the visual-acuity AUC over a 2-year period, a standard deviation of 8.7 letters with adjustment for baseline visual acuity,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-4" href-manipulated="true" aria-label="Reference 5">5</a></sup> a type I error of 5%, and a projection that 15% of the patients would be lost to follow-up.</div><div role="paragraph">The primary analysis followed the intention-to-treat principle according to treatment group and included all the eyes that had undergone randomization. Missing values for visual acuity at follow-up visits were imputed with Markov chain Monte Carlo multiple imputation. Outlying values were truncated to ±3 SD from the mean of the visual-acuity distribution at 104 weeks. The primary analysis of the time-averaged mean score used a linear mixed-effects model with robust variance estimation and a random intercept to account for the correlation in outcome between two eyes in a patient, with adjustment for baseline visual acuity and number of study eyes in the same patient. Prespecified subgroup analyses evaluated the effects of baseline central subfield thickness and visual acuity. Secondary outcomes were compared with the use of linear mixed models or logistic regression with a random intercept term or a Student’s t-test for two independent samples (number of visits). Systemic safety outcomes were compared among three groups with the use of Fisher’s exact test, and global P values are reported. Ocular safety outcomes were compared with the use of Barnard’s unconditional exact test.</div><div role="paragraph">Means with standard deviations or medians with interquartile ranges are reported. All P values and 95% confidence intervals are two-sided. As prespecified, no P values are presented for secondary efficacy outcome measures. No adjustment for multiplicity in sensitivity, subgroup, or safety analyses was implemented. The widths of the confidence intervals are not adjusted for multiple comparisons and should not be used to infer treatment effects. Analyses were performed with the use of SAS/STAT software, version 15.1 (SAS Institute).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Trial Patients</h3><div role="paragraph">Between December 8, 2017, and November 25, 2019, a total of 312 eyes in 270 patients were randomly assigned to receive aflibercept monotherapy (158 eyes) or bevacizumab-first therapy (154 eyes). The median age of the patients was 61 years (interquartile range, 54 to 66); 48% of the patients were women. A total of 53% of the patients were White, 26% were Hispanic or Latino, and 19% were Black or African American; the remaining patients were Asian, Native Hawaiian or other Pacific Islander, or of more than one race or ethnic group or had unknown or unreported race or ethnic group. (Percentages for baseline characteristics are based on numbers of eyes that had undergone randomization rather than on numbers of patients.) The median visual-acuity letter score at baseline was 60 (interquartile range, 65 to 52; approximate Snellen equivalent, 20/63), and the median baseline central subfield thickness was 488 μm (interquartile range, 404 to 616). The baseline characteristics of the patients and eyes were similar in the two groups (<a href="#t2">Table 2</a> and Table S1). With the exclusion of the 14 patients who died, 88% of the patients (226 of 256) completed the 2-year trial (Fig S1). The mean (±SD) number of visits that were completed over the 2-year period in patients with one study eye was 22.0±3.6 among the 98 patients in the aflibercept-monotherapy group and 22.5±3.4 among the 94 patients in the bevacizumab-first group (<a href="#t3">Table 3</a> and Table S2).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/cfb6a2ed-41f1-4903-86aa-b0e5c84c5e9c/assets/images/large/nejmoa2204225_t2.jpg" height="3344" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Aflibercept-Monotherapy<br>Group<br>(N=158 eyes)</th><th class="txxr-borders">Bevacizumab-First<br>Group<br>(N=154 eyes)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Patient characteristics</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of study eyes</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">116 (73)</td><td class="xxxr-borders shading">112 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">42 (27)</td><td class="xxxr-borders">42 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">60 (55 to 66)</td><td class="xxxr-borders shading">61 (54 to 67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">76 (48)</td><td class="xxxr-borders">74 (48)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">82 (52)</td><td class="xxxr-borders">83 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black or African American</td><td class="xxxx-borders shading">32 (20)</td><td class="xxxr-borders shading">26 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hispanic or Latino</td><td class="xxxx-borders">39 (25)</td><td class="xxxr-borders">41 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Native Hawaiian or other Pacific Islander</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Multiple</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown or not reported</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Type of diabetes — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">7 (4)</td><td class="xxxr-borders shading">8 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">151 (96)</td><td class="xxxr-borders">146 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median duration of diabetes (IQR) — yr</td><td class="xxxx-borders shading">15 (9 to 21)</td><td class="xxxr-borders shading">14 (5 to 21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median glycated hemoglobin (IQR) — %<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">8.0 (7.2 to 9.4)</td><td class="xxxr-borders">8.0 (6.8 to 9.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Study eye characteristics</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median visual-acuity letter score (IQR)<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">61 (65 to 54)</td><td class="xxxr-borders">60 (65 to 51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median visual-acuity Snellen equivalent (IQR)</td><td class="xxxx-borders shading">20/63<br>(20/65 to 20/80)</td><td class="xxxr-borders shading">20/63<br>(20/50 to 20/100)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Distribution according to visual acuity — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">68 to 54 letters; Snellen equivalent, 20/50 to 20/80</td><td class="xxxx-borders shading">119 (75)</td><td class="xxxr-borders shading">111 (72)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">53 to 39 letters; Snellen equivalent, 20/100 to 20/160</td><td class="xxxx-borders">28 (18)</td><td class="xxxr-borders">31 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">38 to 24 letters; Snellen equivalent, 20/200 to 20/320</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxr-borders shading">12 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median central subfield thickness on OCT (IQR) — μm<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">478 (401 to 579)</td><td class="xxxr-borders">496 (407 to 628)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Diabetic Retinopathy Severity Scale — no./total no. (%)<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diabetic retinopathy absent or questionable; levels 10, 12, 14, or 15</td><td class="xxxx-borders">0/151</td><td class="xxxr-borders">1/147 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Microaneurysms only; level 20</td><td class="xxxx-borders shading">0/151</td><td class="xxxr-borders shading">2/147 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mild-to-moderate nonproliferative diabetic retinopathy; level 35 or 43</td><td class="xxxx-borders">58/151 (38)</td><td class="xxxr-borders">42/147 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Moderately severe to severe nonproliferative diabetic retinopathy; level 47 or 53</td><td class="xxxx-borders shading">72/151 (48)</td><td class="xxxr-borders shading">79/147 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mild-to-moderate proliferative diabetic retinopathy; level 61 or 65</td><td class="xxxx-borders">15/151 (10)</td><td class="xxxr-borders">16/147 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High-risk proliferative diabetic retinopathy; level 71 or 75</td><td class="xxxx-borders shading">6/151 (4)</td><td class="xxxr-borders shading">7/147 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Previous anti-VEGF treatment for diabetic macular edema — no. (%)</td><td class="xbxx-borders">25 (16)</td><td class="xbxr-borders">29 (19)</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients and Study Eyes at Baseline.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Percentages for baseline characteristics are based on numbers of eyes that had undergone randomization rather than on numbers of patients. The 42 patients with two study eyes had one eye in each treatment group. Percentages may not total 100 because of rounding. IQR denotes interquartile range, OCT optical coherence tomography, and VEGF vascular endothelial growth factor.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Race and ethnic group were reported by the patient on the basis of fixed categories.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup></div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Data on the glycated hemoglobin level were unavailable for 10 eyes in each trial group.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">The visual-acuity score was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, &lt;20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78+0.95×Cirrus score.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> Data were unavailable for two eyes in the aflibercept-monotherapy group; the reading center confirmed the presence of diabetic macular edema in these eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">Severity levels include 12 discrete steps ranging from 10 to 85, with higher levels indicating greater severity.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-2" href-manipulated="true" aria-label="Reference 9">9</a></sup> Level was based on assessment by the reading center. Data were not available for one eye in the bevacizumab-first group. Eyes could not be graded for seven eyes in the aflibercept-monotherapy group and for six eyes in the bevacizumab-first group. Percentages are based on the numbers of eyes with gradable severity of diabetic retinopathy at baseline. No eyes had a severity level of 81 or 85 (indicating advanced proliferative diabetic retinopathy).</div></div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/dc2c2617-5b65-4c8d-8276-eac4fa7368e5/assets/images/large/nejmoa2204225_t3.jpg" height="3438" width="1962" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcomes</th><th class="txxx-borders">Aflibercept-Monotherapy<br>Group<br>(N=132 eyes)</th><th class="txxx-borders">Bevacizumab-First<br>Group<br>(N=128 eyes)</th><th class="txxr-borders">Adjusted Difference<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Visual-acuity letter score</b><a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Primary outcome: change in visual acuity from baseline over the 2-yr period</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">15.0±8.5</td><td class="xxxx-borders shading">14.0±8.8</td><td class="xxxr-borders shading">0.8 (−0.9 to 2.5)<a href="#t3fn3" role="doc-noteref">‡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders">14.8 (9.2 to 20.9)</td><td class="xxxx-borders">13.2 (8.3 to 18.7)</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Visual acuity at 2 yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Letter score</td><td class="xxxx-borders">72±15</td><td class="xxxx-borders">73±13</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean Snellen equivalent</td><td class="xxxx-borders shading">20/40</td><td class="xxxx-borders shading">20/40</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Visual acuity — no. of eyes (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">20/20 or better</td><td class="xxxx-borders shading">29 (22)</td><td class="xxxx-borders shading">28 (22)</td><td class="xxxr-borders shading">−1 (−11 to 8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">20/40 or better</td><td class="xxxx-borders">96 (73)</td><td class="xxxx-borders">95 (74)</td><td class="xxxr-borders">−7 (−19 to 5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">20/200 or worse</td><td class="xxxx-borders shading">6 (5)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (−1 to 7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Mean change from baseline in letter score at 2 yr</td><td class="xxxx-borders">14.7±14.5</td><td class="xxxx-borders">15.9±12.4</td><td class="xxxr-borders">−1.8 (−4.9 to 1.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Improvement in no. of letters — no. of eyes (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">By ≥15 letters</td><td class="xxxx-borders">70 (53)</td><td class="xxxx-borders">74 (58)</td><td class="xxxr-borders">−7 (−21 to 8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">By ≥10 letters</td><td class="xxxx-borders shading">101 (77)</td><td class="xxxx-borders shading">98 (77)</td><td class="xxxr-borders shading">−3 (−13 to 8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Worsening in no. of letters — no. of eyes (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">By ≥10 letters</td><td class="xxxx-borders shading">9 (7)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">4 (−2 to 9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">By ≥15 letters</td><td class="xxxx-borders">8 (6)</td><td class="xxxx-borders">4 (3)</td><td class="xxxr-borders">3 (−1 to 8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Central subfield thickness on OCT<a href="#t3fn4" role="doc-noteref">§</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">At 2 yr — μm</td><td class="xxxx-borders">315±93</td><td class="xxxx-borders">336±100</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Value below the sex-specific threshold for central-involved diabetic macular edema at 2 yr — no./total no. (%)<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">76/126 (60)</td><td class="xxxx-borders shading">70/127 (55)</td><td class="xxxr-borders shading">4 (−12 to 20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Change from baseline at 2 yr — μm</td><td class="xxxx-borders">−192±143</td><td class="xxxx-borders">−198±160</td><td class="xxxr-borders">−16 (−39 to 7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left"><b>No. of trial visits completed over the 2-yr period<a href="#t3fn6" role="doc-noteref">‖</a></b></td><td class="xxxx-borders shading">22.0±3.6</td><td class="xxxx-borders shading">22.5±3.4</td><td class="xxxr-borders shading">−0.5 (−1.5 to 0.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>No. of trial injections administered<a href="#t3fn7" role="doc-noteref">**</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">&lt;24 wk</td><td class="xxxx-borders shading">5.7±0.7</td><td class="xxxx-borders shading">5.8±0.5</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">≥24 wk and &lt;1 yr</td><td class="xxxx-borders">3.7±1.8</td><td class="xxxx-borders">4.2±1.8</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">&lt;1 yr</td><td class="xxxx-borders shading">9.3±2.1</td><td class="xxxx-borders shading">10.0±2.0</td><td class="xxxr-borders shading">−0.6 (−1.0 to −0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">≥1 yr and ≤2 yr</td><td class="xxxx-borders">5.3±2.8</td><td class="xxxx-borders">6.1±3.1</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">≤2 yr</td><td class="xbxx-borders shading">14.6±4.1</td><td class="xbxx-borders shading">16.1±4.1</td><td class="xbxr-borders shading">−1.5 (−2.4 to −0.5)</td></tr></tbody></table></div><figcaption><div class="caption">Trial Outcomes through 2 Years of Follow-up.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Plus–minus values are means ±SD. Descriptive statistics (i.e., means with standard deviations, medians with IQRs, and percentages) are reported for eyes in patients who completed the 2-year trial, unless otherwise noted.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, &lt;20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up. Missing data in visual-acuity measurements during follow-up were imputed with the use of multiple imputation for eyes in patients not completing the 2-year visit or when data were otherwise noted as missing, under an assumption that data were missing at random. Outlying values were truncated to ±3 SD from the observed mean at 104 weeks; 14 of 4685 observed visual-acuity values (0.3%) were truncated in the calculation of the AUC. The AUC outcome was calculated after multiple imputation and data truncation were applied, with the use of all observed and imputed data points for each patient. Continuous outcomes were compared between treatment groups with the use of a linear mixed-effects model with a random intercept term (for the correlation between two study eyes in the same patient) and robust variance estimation, with adjustment for baseline visual acuity and number of study eyes. Binary outcomes were compared with the use of logistic regression with a random intercept (for the correlation between two study eyes in the same patient), conditional standardization, and the delta method (for the estimation of risk difference), with adjustment for baseline visual acuity and number of study eyes. Adjustment for baseline visual acuity, number of study eyes, and the correlation between the two study eyes in the same patient were removed from the model only when there was a convergence issue.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">P=0.37.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">Data were available for 126 eyes in the aflibercept-monotherapy group and for 127 eyes in the bevacizumab-first group. Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78+0.95×Cirrus score.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-2" href-manipulated="true" aria-label="Reference 11">11</a></sup> The analysis included only eyes for which baseline data on the central subfield thickness were available. Data on the central subfield thickness at 104 weeks were unavailable for 5 eyes in the aflibercept-monotherapy group and for 1 eye in the bevacizumab-first group. Missing data were imputed with the use of multiple imputation. Comparison of treatment groups was performed with the use of a linear mixed-effects model with a random intercept term for patients and robust variance estimation, with adjustment for baseline central subfield thickness and number of study eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">The OCT thresholds were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus device (Zeiss).<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-2" href-manipulated="true">7,8</a></sup> There was no imputation for this outcome because the threshold values are machine-specific and not Spectralis equivalents, which were imputed. Comparison of treatment groups was performed with the use of logistic regression with a random intercept (for the correlation between two study eyes in the same patient), conditional standardization, and the delta method (for the estimation of risk difference).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t3fn6" role="paragraph">This analysis was limited to patients with one study eye who completed 2 years of follow-up. Data were available for 98 eyes in the aflibercept-monotherapy group and for 94 eyes in the bevacizumab-first group.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t3fn7" role="paragraph">The analyses were limited to eyes in patients who completed the visit or any later common visit. All the trial injections were counted, including aflibercept injections that were administered to eyes in the bevacizumab-first group. Estimated differences were adjusted for the number of study eyes in the same patient and the correlation between two study eyes in the same patient. Data were available up to 24 weeks for 148 eyes in the aflibercept-monotherapy group and for 146 eyes in the bevacizumab-first group and up to 1 year for 144 and 142 eyes, respectively.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Trial Treatments</h3><div role="paragraph">Over the 2-year trial period, eyes in the aflibercept-monotherapy group received a mean of 14.6±4.1 injections and those in the bevacizumab-first group received 16.1±4.1 injections (adjusted difference, −1.5 injections; 95% confidence interval [CI], −2.4 to −0.5) (<a href="#t3">Table 3</a>). Eyes in the bevacizumab-first group received a mean of 9.2±5.2 bevacizumab injections and 6.9±5.8 aflibercept injections over the 2-year period. Overall, 153 eyes (97%) in the aflibercept-monotherapy group and 147 (95%) in the bevacizumab-first group adhered to the trial-injection protocol (Table S3). The cumulative percentage of eyes in the bevacizumab-first group that were switched to aflibercept therapy was 39% (95% CI, 32 to 47) up to 24 weeks, 60% (95% CI, 53 to 68) up to 52 weeks, and 70% (95% CI, 62 to 77) over the 2-year period (<a href="#f1">Figure 1</a>). Among the 100 eyes that were switched to aflibercept therapy, 57 (57%) met the criteria between 12 weeks and 24 weeks. The cumulative percentage of eyes in the aflibercept-monotherapy group that met the protocol-defined criteria (but continued aflibercept treatment as prespecified) was 13% (95% CI, 9 to 20) up to 24 weeks, 26% (95% CI, 20 to 34) up to 52 weeks, and 30% (95% CI, 23 to 38) over the 2-year period (Fig. S3). On completion of the 2-year visit, 188 patients with one study eye were asked whether they believed they knew which drugs they had received, and if they did, to indicate which drug: 108 of 188 patients (57%) did not know or declined to answer; 46 of the 80 patients (58%) who provided a full response selected the correct treatment, and 34 (42%) did not select correctly.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f1.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/6868cb6f-1e78-403c-b730-0c246fec4547/assets/images/large/nejmoa2204225_f1.jpg" height="1596" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Time from Randomization to Meeting the Switching Criteria among Eyes Assigned to the Bevacizumab-First Group.</div><div class="notes"><div role="doc-footnote">The criteria for switching to aflibercept monotherapy were persistent center-involved diabetic macular edema (defined as a central subfield thickness above the eligibility threshold), an adequately treated eye (administration of bevacizumab at the previous two consecutive trial visits), no recent improvement in eye condition (no improvement in visual acuity by ≥5 letters and no decrease in central subfield thickness by ≥10% as compared with each of the two preceding visits or between each of the two preceding visits), and suboptimal vision (visual acuity, 20/50 or worse before 24 weeks or 20/32 or worse at 24 weeks or later). Data for eyes that did not meet the criteria for switching to aflibercept therapy were censored at the last completed visit.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Primary Outcome</h3><div role="paragraph">The mean change in visual acuity from baseline over the 2-year trial period (AUC) was 15.0±8.5 letters in the aflibercept-monotherapy group and 14.0±8.8 letters in the bevacizumab-first group (adjusted difference, 0.8 letters; 95% CI, −0.9 to 2.5; P=0.37) (<a href="#t3">Table 3</a> and <a href="#f2">Figure 2A</a>). Sensitivity analyses, including a comparison that involved only the 42 patients with one study eye assigned to each treatment group, yielded results that were consistent with the primary analysis (Table S4). The adjusted mean difference in the letter scores between eyes treated with aflibercept monotherapy and eyes treated with bevacizumab first was −1.6 letters (95% CI, −4.4 to 1.2) among eyes with a baseline central subfield thickness of less than 400 μm and 2.4 letters (95% CI, 0.2 to 4.7) among eyes with a baseline central subfield thickness of at least 400 μm (Table S5).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f2.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/fad22fbb-1ff0-4d41-b37c-a29580f9e2d4/assets/images/large/nejmoa2204225_f2.jpg" height="3260" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Mean Changes in Visual Acuity and Central Subfield Thickness through 2 Years.</div><div class="notes"><div role="doc-footnote">Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 0 letters (Snellen equivalent, &lt;20/800) to 100 letters (Snellen equivalent, 20/10), with higher scores indicating better visual acuity.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> The data shown are the best-corrected visual acuity in the study eye after protocol-defined refraction (Panel A). Central subfield thickness was measured by optical coherence tomographic scans (Panel B). Measurements made on the Cirrus device were converted to equivalent scores on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-3" href-manipulated="true" aria-label="Reference 11">11</a></sup> In both panels, 𝙸 bars indicate 95% confidence intervals. Data are shown slightly offset at each time point for better visibility.</div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Secondary Outcomes</h3><div role="paragraph">At 2 years, the mean change in visual acuity from baseline was 14.7±14.5 letters in the aflibercept-monotherapy group (in 132 eyes) and 15.9±12.4 letters in the bevacizumab-first group (in 128 eyes), with an adjusted between-group difference of −1.8 letters (95% CI, −4.9 to 1.2) (<a href="#t3">Table 3</a>). In each group, 77% of the eyes had an improvement in visual acuity of at least 10 letters (adjusted difference, −3 percentage points; 95% CI, −13 to 8), and 22% in each group had visual acuity of 20/20 or better (adjusted difference, −1 percentage point; 95% CI, −11 to 8). Visual acuity of 20/40 or better at 2 years was observed in 73% of the eyes in the aflibercept-monotherapy group and in 74% of those in the bevacizumab-first group (adjusted difference, −7 percentage points; 95% CI, −19 to 5).</div><div role="paragraph">The mean change in the central subfield thickness from baseline to 2 years was −192±143 μm in the aflibercept-monotherapy group (in 126 eyes) and −198±160 μm in the bevacizumab-first group (in 127 eyes), with an adjusted between-group difference of −16 μm (95% CI, −39 to 7) (<a href="#t3">Table 3</a> and <a href="#f2">Figure 2B</a>). Although a greater reduction in the central subfield thickness was observed in the aflibercept-monotherapy group than in the bevacizumab-first group at 24 weeks and 52 weeks (Table S6), the percentages of eyes at 2 years with a central subfield thickness below thresholds for diabetic macular edema were similar in the two groups: 60% in the aflibercept-monotherapy group and 55% in the bevacizumab-first group (adjusted difference, 4 percentage points; 95% CI, −12 to 20).</div><div role="paragraph">At 2 years, an improvement of at least two steps in the severity of diabetic retinopathy occurred in 53 of 105 eyes (50%) in the aflibercept-monotherapy group and in 60 of 108 eyes (56%) in the bevacizumab-first group (adjusted difference, −3 percentage points; 95% CI, −23 to 17). Few eyes had a worsening in severity of at least two steps (4% in each group; adjusted difference, 0 percentage points; 95% CI, −5 to 5).</div></section><section id="sec-2-5"><h3>Adverse Events</h3><div role="paragraph">Endophthalmitis developed in one eye in the aflibercept-monotherapy group. Prespecified ocular adverse events were infrequent in the two treatment groups (<a href="#t4">Table 4</a>). At least one serious systemic adverse event occurred in 60 of 116 patients (52%) in the aflibercept-monotherapy group, in 40 of 112 (36%) in the bevacizumab-first group, and in 18 of 42 (43%) among patients with two study eyes (P=0.05). At least one hospitalization occurred in 56 patients (48%) in the aflibercept-monotherapy group, in 36 (32%) in the bevacizumab-first group, and in 18 (43%) among patients with two study eyes (P=0.04). The incidence of any adverse event as defined by the Antiplatelet Trialists’ Collaboration was 12% in the aflibercept-monotherapy group, 8% in the bevacizumab-first group, and 7% among patients with two study eyes (P=0.57) (<a href="#t4">Table 4</a>). All the adverse events are listed in Tables S7 through S11.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 4</div><nav><a href="#t4" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t4" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/5b9304a0-d736-4a2b-8fb7-9fd27f0d2e89/assets/images/large/nejmoa2204225_t4.jpg" height="2771" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Aflibercept-Monotherapy<br>Group</th><th class="txxx-borders">Bevacizumab-First<br>Group</th><th class="txxx-borders">Patients with<br>Two Study Eyes</th><th class="txxr-borders">P Value</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Systemic adverse events</b><a href="#t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">116</td><td class="xxxx-borders">112</td><td class="xxxx-borders">42</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Vascular events defined by APTC criteria — no. (%)<a href="#t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonfatal myocardial infarction</td><td class="xxxx-borders">3 (3)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0.52</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonfatal stroke</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxx-borders shading">6 (5)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxr-borders shading">0.56</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Death due to potential vascular cause or unknown cause</td><td class="xxxx-borders">8 (7)</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">2 (5)</td><td class="xxxr-borders">0.14</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">14 (12)</td><td class="xxxx-borders shading">9 (8)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxr-borders shading">0.57</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Prespecified adverse events — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death from any cause</td><td class="xxxx-borders shading">10 (9)</td><td class="xxxx-borders shading">4 (4)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxr-borders shading">0.28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hospitalization</td><td class="xxxx-borders">56 (48)</td><td class="xxxx-borders">36 (32)</td><td class="xxxx-borders">18 (43)</td><td class="xxxr-borders">0.04<a href="#t4fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">60 (52)</td><td class="xxxx-borders shading">40 (36)</td><td class="xxxx-borders shading">18 (43)</td><td class="xxxr-borders shading">0.05</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypertension</td><td class="xxxx-borders">19 (16)</td><td class="xxxx-borders">10 (9)</td><td class="xxxx-borders">11 (26)</td><td class="xxxr-borders">0.02<a href="#t4fn5" role="doc-noteref">¶</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Ocular adverse events</b><a href="#t4fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of eyes</td><td class="xxxx-borders">158</td><td class="xxxx-borders">154</td><td class="xxxx-borders">—</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Endophthalmitis — no. (%)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.52</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any retinal detachment — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.08</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Rhegmatogenous retinal detachment</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Traction retinal detachment</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Traumatic cataract — no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Vitreous hemorrhage — no. (%)</td><td class="xxxx-borders">7 (4)</td><td class="xxxx-borders">10 (6)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.53</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Ocular inflammation — no. (%)<a href="#t4fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.53</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Intraocular-pressure elevation — no. (%)<a href="#t4fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">15 (9)</td><td class="xxxx-borders">14 (9)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.92</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Increase in intraocular pressure ≥10 mm Hg from baseline</td><td class="xxxx-borders shading">10 (6)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intraocular pressure ≥30 mm Hg</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Initiation of medication to lower intraocular pressure that was not in use at baseline</td><td class="xxxx-borders shading">7 (4)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Procedure to treat glaucoma</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neovascularization of the iris — no. (%)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.21</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Neovascular glaucoma — no. (%)</td><td class="xbxx-borders">1 (1)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">—</td><td class="xbxr-borders">0.52</td></tr></tbody></table></div><figcaption><div class="caption">Systemic and Ocular Adverse Events of Special Interest through 2 Years of Follow-up.<a href="#t4fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t4fn1" role="paragraph">Unless otherwise specified, data on adverse events were collected at any time during trial follow-up. Some events may have been reported more than once (i.e., at multiple visits). Analyses included patients and study eyes that had at least one adverse event of interest. All the adverse events except intraocular-pressure events were reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t4fn2" role="paragraph">The percentages of patients with each systemic adverse event were compared among the three groups with the use of Fisher’s exact test, and global P values are reported. Pairwise comparisons between groups were conducted only if the overall test had a P value of 0.05 or less, with the use of Fisher’s exact test without adjustment for multiple comparisons.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t4fn3" role="paragraph">Vascular events (those that were definitely or possibly vascular, which included all deaths attributed to cardiac, cerebral, hemorrhagic, embolic, other vascular, or unknown causes) were defined according to the criteria of the Antiplatelet Trialists’ Collaboration (APTC).<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup></div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t4fn4" role="paragraph">P=0.02 for the comparison of the aflibercept-monotherapy group with the bevacizumab-first group, 0.59 for the comparison of the aflibercept-monotherapy group with the group of patients with two study eyes, and 0.26 for the comparison of the bevacizumab-first group with the group of patients with two study eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t4fn5" role="paragraph">P=0.11 for the comparison of the aflibercept-monotherapy group with the bevacizumab-first group, 0.17 for the comparison of the aflibercept-monotherapy group with the group of patients with two study eyes, and 0.009 for the comparison of the bevacizumab-first group with the group of patients with two study eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t4fn6" role="paragraph">The percentages of eyes that had each outcome were compared between treatment groups with the use of Barnard’s unconditional exact test, with the number of eyes in each treatment group as a fixed margin.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t4fn7" role="paragraph">Inflammation included the presence of inflammatory cells or flare in the anterior chamber, pseudohypopyon, chorioretinitis, choroiditis, pseudoendophthalmitis, iritis, uveitis, and the presence of vitreal cells.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t4fn8" role="paragraph">Intraocular-pressure elevation was defined as an increase in intraocular pressure of 10 mm Hg or more from baseline at any visit, an intraocular pressure of 30 mm Hg or more at any visit, the initiation of medication to lower intraocular pressure that was not in use at baseline, or procedure to treat glaucoma.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this randomized clinical trial involving eyes with center-involved diabetic macular edema and moderately impaired vision of 20/50 or worse, there was no overall significant difference in the mean change in vision over a 2-year period with either aflibercept monotherapy or with the administration of bevacizumab first plus a switch to aflibercept therapy on the basis of prespecified criteria for suboptimal response. There was also no difference in retinal thickness between the groups at 2 years. Approximately 70% of the patients in the bevacizumab-first group had treatment switched to aflibercept during the 2-year trial. More than half these patients (57%) had treatment switched between 12 weeks and 24 weeks. These results expand our understanding of how and whether clinical outcomes differ with the use of various anti-VEGF treatment strategies for diabetic macular edema.</div><div role="paragraph">Previously, the DRCR Retina Network Protocol T trial showed that eyes with visual acuity worse than 20/50 had better visual-acuity and retinal-thickness outcomes with aflibercept monotherapy than with bevacizumab monotherapy.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-5" href-manipulated="true" aria-label="Reference 5">5</a></sup> Unsurprisingly, given these findings, the visual-acuity and retinal-thickness outcomes in the current trial appeared to favor aflibercept monotherapy over the bevacizumab-first strategy throughout the first year. However, rescue treatment with aflibercept mitigated the mean visual and anatomical differences that arose from the initiation of therapy with bevacizumab or aflibercept. A post hoc sensitivity analysis involving study eyes in the subgroup of patients who were treated in one eye with aflibercept monotherapy and in the other eye with bevacizumab first did not identify significant differences in visual outcomes between the trial groups. The trial population had higher proportions of persons of color, in the aggregate, than the U.S. population (Table S12), but the proportions were similar enough to those in the U.S. population that the trial results are probably generalizable. Black or African American persons are disproportionately affected by diabetic macular edema and were overrepresented in the trial. A limitation, however, is the underrepresentation of Asians and no representation of Native Americans or Alaska Natives.</div><div role="paragraph">In a prespecified secondary analysis involving the subgroup of eyes with baseline central subfield thickness of at least 400 μm, eyes that were treated with aflibercept monotherapy had a better mean change in visual acuity from baseline over the 2-year period than eyes treated with bevacizumab first (adjusted difference, 2.4 letters; 95% CI, 0.2 to 4.7). However, the width of the confidence interval is not adjusted for multiple comparisons and cannot be used to infer treatment effects, and a difference of this magnitude is of marginal clinical relevance.</div><div role="paragraph">Findings from this trial are particularly relevant given the increasing frequency of insurers mandating step therapy with bevacizumab before the use of other drugs that have been approved by the FDA. However, the results from this trial can be generalized only to patients who receive therapy according to the same switching criteria, anti-VEGF agents, and retreatment algorithm as were used in this trial. Given the difference between the drugs in cost — by approximately a factor of 26 (Medicare reimbursement, approximately $1,830 for one dose of aflibercept and $70 for one dose of bevacizumab)<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15" id="body-ref-r15" href-manipulated="true">14,15</a></sup> — the initiation of treatment with bevacizumab could have substantial cost reductions for the health care system.</div><div role="paragraph">There was a higher frequency of serious systemic adverse events in the aflibercept-monotherapy group (52%) than in the bevacizumab-first group (36%), and the incidence of hospitalization was 48% and 32%, respectively. Previous trials of aflibercept monotherapy for diabetic macular edema have shown similar incidences of adverse events as compared with sham treatment and as compared with bevacizumab monotherapy.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r16 r17" id="body-ref-r17" href-manipulated="true">5,16,17</a></sup></div><div role="paragraph">This trial has limitations. First, it is unknown whether milder or stricter switching criteria would have led to different results. Second, although efforts were made to keep patients unaware of their treatment assignment, the cost of aflibercept in this trial was generally billed to the patients’ insurance when applicable; therefore, patients may have become aware of the treatment assignment if they viewed billing information. However, when patients were asked about the treatment they had received, 57% did not know or declined to answer; among patients who made a guess, 42% did so incorrectly. Third, besides aflibercept, this trial did not include other anti-VEGF agents that have been approved by the FDA for the treatment of diabetic macular edema.</div><div role="paragraph">In this trial involving eyes with moderate vision loss due to diabetic macular edema in the center of the macula, we found no evidence of significant difference in visual outcomes over a period of 2 years in eyes treated with aflibercept monotherapy as compared with eyes treated with bevacizumab first.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="disclaimer" role="paragraph">The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</div><div data-type="published/updated" role="paragraph">This article was published on July 14, 2022, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a grant (UG1EY014231) from the <span class="named-content" data-type="funder">National Eye Institute</span> and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2204225_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204225/suppl_file/nejmoa2204225_research-summary.pdf" download="nejmoa2204225_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204225_research-summary.pdf" data-doi="10.1056/NEJMoa2204225">Download</a></li><li>1011.93 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2204225_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204225/suppl_file/nejmoa2204225_protocol.pdf" download="nejmoa2204225_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204225_protocol.pdf" data-doi="10.1056/NEJMoa2204225">Download</a></li><li>1.85 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2204225_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204225/suppl_file/nejmoa2204225_appendix.pdf" download="nejmoa2204225_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204225_appendix.pdf" data-doi="10.1056/NEJMoa2204225">Download</a></li><li>448.19 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2204225_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204225/suppl_file/nejmoa2204225_disclosures.pdf" download="nejmoa2204225_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204225_disclosures.pdf" data-doi="10.1056/NEJMoa2204225">Download</a></li><li>1.46 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2204225_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204225/suppl_file/nejmoa2204225_data-sharing.pdf" download="nejmoa2204225_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204225_data-sharing.pdf" data-doi="10.1056/NEJMoa2204225">Download</a></li><li>69.88 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern. <em>Ophthalmology</em> 2020;127(1):P66-P145.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2019.09.025" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31757498/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503224300010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diabetic+retinopathy+preferred+practice+pattern.&amp;publication_year=2020&amp;journal=Ophthalmology&amp;pages=P66-P145&amp;doi=10.1016%2Fj.ophtha.2019.09.025&amp;pmid=31757498" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cause of vision loss in working-age adults. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] factor (anti-VEGF) agents into the eye. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. <em>Eye Vis (Lond)</em> 2015;2:17-17.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s40662-015-0026-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26605370/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457289400017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiology+of+diabetic+retinopathy%2C+diabetic+macular+edema+and+related+vision+loss.&amp;publication_year=2015&amp;journal=Eye+Vis+%28Lond%29&amp;pages=17-17&amp;doi=10.1186%2Fs40662-015-0026-2&amp;pmid=26605370" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. <em>Ophthalmology</em> 2012;119:789-801.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2011.12.039" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22330964/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302355400018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ranibizumab+for+diabetic+macular+edema%3A+results+from+2+phase+III+randomized+trials%3A+RISE+and+RIDE.&amp;publication_year=2012&amp;journal=Ophthalmology&amp;pages=789-801&amp;doi=10.1016%2Fj.ophtha.2011.12.039&amp;pmid=22330964" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. <em>Ophthalmology</em> 2015;122:2044-2052.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2015.06.017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26198808/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363491500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravitreal+aflibercept+for+diabetic+macular+edema%3A+100-week+results+from+the+VISTA+and+VIVID+studies.&amp;publication_year=2015&amp;journal=Ophthalmology&amp;pages=2044-2052&amp;doi=10.1016%2Fj.ophtha.2015.06.017&amp;pmid=26198808" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. <em>Ophthalmology</em> 2016;123:1351-1359.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2016.02.022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26935357/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376506400033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Aflibercept%2C+bevacizumab%2C+or+ranibizumab+for+diabetic+macular+edema%3A+two-year+results+from+a+comparative+effectiveness+randomized+clinical+trial.&amp;publication_year=2016&amp;journal=Ophthalmology&amp;pages=1351-1359&amp;doi=10.1016%2Fj.ophtha.2016.02.022&amp;pmid=26935357" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] are effective in improving visual acuity. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] baseline visual acuity of 20/40 or better, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] through 1 year than ranibizumab therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] with adjustment for baseline visual acuity, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] than with bevacizumab monotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] as compared with bevacizumab monotherapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Sachs RE, Kyle MA. Step therapy’s balancing act — protecting patients while addressing high drug prices. <em>N Engl J Med</em> 2022;386:901-904.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2204225&amp;key=10.1056%2FNEJMp2117582&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35245014/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000764894200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Step+therapy%E2%80%99s+balancing+act+%E2%80%94+protecting+patients+while+addressing+high+drug+prices.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=901-904&amp;doi=10.1056%2FNEJMp2117582&amp;pmid=35245014" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Chalam KV, Bressler SB, Edwards AR, et al. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. <em>Invest Ophthalmol Vis Sci</em> 2012;53:8154-8161.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1167/iovs.12-10290" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23132803/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000313056000033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Retinal+thickness+in+people+with+diabetes+and+minimal+or+no+diabetic+retinopathy%3A+Heidelberg+Spectralis+optical+coherence+tomography.&amp;publication_year=2012&amp;journal=Invest+Ophthalmol+Vis+Sci&amp;pages=8154-8161&amp;doi=10.1167%2Fiovs.12-10290&amp;pmid=23132803" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on optical coherence tomography (OCT). </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r7-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] respectively on the Cirrus device (Zeiss). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. <em>JAMA</em> 2015;314:2137-2146.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2015.15217" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26565927/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365351900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Panretinal+photocoagulation+vs+intravitreous+ranibizumab+for+proliferative+diabetic+retinopathy%3A+a+randomized+clinical+trial.&amp;publication_year=2015&amp;journal=JAMA&amp;pages=2137-2146&amp;doi=10.1001%2Fjama.2015.15217&amp;pmid=26565927" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on optical coherence tomography (OCT). </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r8-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] respectively on the Cirrus device (Zeiss). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Grading diabetic retinopathy from stereoscopic color fundus photographs — an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. <em>Ophthalmology</em> 1991;98:786-806.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0161-6420(13)38012-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2062513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1991FL41900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Grading+diabetic+retinopathy+from+stereoscopic+color+fundus+photographs+%E2%80%94+an+extension+of+the+modified+Airlie+House+classification.+ETDRS+report+number+10.+Early+Treatment+Diabetic+Retinopathy+Study+Research+Group.&amp;publication_year=1991&amp;journal=Ophthalmology&amp;pages=786-806&amp;doi=10.1016%2FS0161-6420%2813%2938012-9&amp;pmid=2062513" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] higher levels indicating greater severity. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r9-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] higher levels indicating greater severity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">National Institutes of Health. Racial and ethnic categories and definitions for NIH diversity programs and for other reporting purposes. April 8, 2015 (<a href="https://grants.nih.gov/grants/guide/notice-files/not-od-15-089.html">https://grants.nih.gov/grants/guide/notice-files/not-od-15-089.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Racial+and+ethnic+categories+and+definitions+for+NIH+diversity+programs+and+for+other+reporting+purposes.&amp;publication_year=2015" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Sun JK, Josic K, Melia M, et al. Conversion of central subfield thickness measurements of diabetic macular edema across Cirrus and Spectralis optical coherence tomography instruments. <em>Transl Vis Sci Technol</em> 2021;10:34-34.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1167/tvst.10.14.34" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34967834/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Conversion+of+central+subfield+thickness+measurements+of+diabetic+macular+edema+across+Cirrus+and+Spectralis+optical+coherence+tomography+instruments.&amp;publication_year=2021&amp;journal=Transl+Vis+Sci+Technol&amp;pages=34-34&amp;doi=10.1167%2Ftvst.10.14.34&amp;pmid=34967834" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r11-1"><i aria-hidden="true" class="icon-return"></i><span>a [...] Spectralis score = 40.78+0.95×Cirrus score. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r11-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] Spectralis score = 40.78+0.95×Cirrus score. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f2" role="menuitem" data-target="#fv-body-ref-r11-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] score = 40.78 + 0.95 × Cirrus score. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. <em>Am J Ophthalmol</em> 2003;135:194-205.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0002-9394(02)01825-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12566024/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000180709400011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+computerized+method+of+visual+acuity+testing%3A+adaptation+of+the+early+treatment+of+diabetic+retinopathy+study+testing+protocol.&amp;publication_year=2003&amp;journal=Am+J+Ophthalmol&amp;pages=194-205&amp;doi=10.1016%2FS0002-9394%2802%2901825-1&amp;pmid=12566024" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. <em>BMJ</em> 1994;308:81-106.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.308.6921.81" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8298418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994MR17300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Collaborative+overview+of+randomised+trials+of+antiplatelet+therapy.+I.+Prevention+of+death%2C+myocardial+infarction%2C+and+stroke+by+prolonged+antiplatelet+therapy+in+various+categories+of+patients.&amp;publication_year=1994&amp;journal=BMJ&amp;pages=81-106&amp;doi=10.1136%2Fbmj.308.6921.81&amp;pmid=8298418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Centers for Medicare and Medicaid Services. 2022 ASP drug pricing files. 2022 (<a href="https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files">https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2022+ASP+drug+pricing+files.&amp;publication_year=2022" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Centers for Medicare and Medicaid Services. Medicare Advantage prior authorization and step therapy for Part B drugs. August 7, 2018 (<a href="https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-prior-authorization-and-step-therapy-part-b-drugs">https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-prior-authorization-and-step-therapy-part-b-drugs</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Medicare+Advantage+prior+authorization+and+step+therapy+for+Part+B+drugs.&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. <em>N Engl J Med</em> 2015;372:1193-1203.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2204225&amp;key=10.1056%2FNEJMoa1414264&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25692915/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000351585900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Aflibercept%2C+bevacizumab%2C+or+ranibizumab+for+diabetic+macular+edema.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1193-1203&amp;doi=10.1056%2FNEJMoa1414264&amp;pmid=25692915" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Heier JS, Korobelnik J-F, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. <em>Ophthalmology</em> 2016;123:2376-2385.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2016.07.032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27651226/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000389509500022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravitreal+aflibercept+for+diabetic+macular+edema%3A+148-week+results+from+the+VISTA+and+VIVID+studies.&amp;publication_year=2016&amp;journal=Ophthalmology&amp;pages=2376-2385&amp;doi=10.1016%2Fj.ophtha.2016.07.032&amp;pmid=27651226" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/8"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">8</span></span> • <span property="datePublished">August 25, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">692</span>-<span property="pageEnd">703</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2204225" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2204225?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: July 14, 2022</div><div><b class="core-label">Published in issue</b>: August 25, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/diabetes" alt="View article keyword Diabetes" data-interactiontype="article_recirculation_click">Diabetes</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/ophthalmology-general" alt="View article keyword Ophthalmology General" data-interactiontype="article_recirculation_click">Ophthalmology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Chirag D.</span> <span property="familyName">Jhaveri</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adam R.</span> <span property="familyName">Glassman</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Frederick L.</span> <span property="familyName">Ferris</span> III, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Danni</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.S.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maureen G.</span> <span property="familyName">Maguire</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John B.</span> <span property="familyName">Allen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carl W.</span> <span property="familyName">Baker</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Browning</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Matthew A.</span> <span property="familyName">Cunningham</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Scott M.</span> <span property="familyName">Friedman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lee M.</span> <span property="familyName">Jampol</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dennis M.</span> <span property="familyName">Marcus</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daniel F.</span> <span property="familyName">Martin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carin M.</span> <span property="familyName">Preston</span>, <span property="honorificSuffix">M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cynthia R.</span> <span property="familyName">Stockdale</span>, <span property="honorificSuffix">M.S.P.H.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Jennifer K.</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, for <span property="author" typeof="Person">the DRCR Retina Network<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Retina Consultants of Austin and the Austin Research Center for Retina — both in Austin, TX (C.D.J.); the Jaeb Center for Health Research, Tampa (A.R.G., D.L., M.G.M., C.M.P., C.R.S.), the Florida Retina Institute, Orlando (M.A.C.), and Florida Retina Consultants, Lakeland (S.M.F.) — all in Florida; Ophthalmic Research Consultants, Waxhaw (F.L.F.), and Southeast Clinical Research Associates (J.B.A.) and Charlotte Eye, Ear, Nose, and Throat Associates (D.B.), Charlotte — all in North Carolina; the Ophthalmology Group, Paducah, KY (C.W.B.); the Feinberg School of Medicine, Northwestern University, Chicago (L.M.J.); the Southeast Retina Center, Augusta, GA (D.M.M.); Cole Eye Institute, Cleveland Clinic, Cleveland (D.F.M.); and the Joslin Diabetes Center, Beetham Eye Institute, and the Department of Ophthalmology, Harvard Medical School, Boston (J.K.S.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Mr. Glassman can be contacted at <a href="mailto:drcrstat2@jaeb.org">drcrstat2@jaeb.org</a> or at the Jaeb Center for Health Research, 15310 Amberly Dr., Suite 350, Tampa, FL 33647.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A list of the members of the DRCR Retina Network is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">60</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2204225" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="832b4e08-f0fb-ad58-0247-b5aacaa4c5ac"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132447835" style="display:inline-block;">
                <img alt="Article has an altmetric score of 609" src="https://badges.altmetric.com/?size=320&amp;score=609&amp;types=mmmmbttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132447835">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_832b4e08-f0fb-ad58-0247-b5aacaa4c5ac" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132447835&amp;tab=news">
          Picked up by <b>77</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132447835&amp;tab=blogs">
          Blogged by <b>4</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132447835&amp;tab=twitter">
          Posted by <b>53</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132447835&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>96</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6e50f3229f214-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2204225"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-8%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2204225%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="60" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sukhum Silpa-archa, </li><li class="list-inline-item cited-by__entry__author">Variya Nganthavee, </li><li class="list-inline-item cited-by__entry__author">Peranut Chotcomwongse, </li><li class="list-inline-item cited-by__entry__author">Pawas Lalitwongsa, </li><li class="list-inline-item cited-by__entry__author">Paisan Ruamviboonsuk, </li></ul><span class="cited-by__entry__title">Revisiting the Role of Intravitreal Triamcinolone in Diabetic Macular Edema: 12-Month Outcomes after Bevacizumab Failure, </span><span class="cited-by__entry__series-title">Ophthalmology and Therapy, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40123-025-01172-5" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40123-025-01172-5</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40123-025-01172-5" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Chunsik Lee, </li><li class="list-inline-item cited-by__entry__author">Myung-Jin Kim, </li><li class="list-inline-item cited-by__entry__author">Anil Kumar, </li><li class="list-inline-item cited-by__entry__author">Han-Woong Lee, </li><li class="list-inline-item cited-by__entry__author">Yunlong Yang, </li><li class="list-inline-item cited-by__entry__author">Yonghwan Kim, </li></ul><span class="cited-by__entry__title">Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives, </span><span class="cited-by__entry__series-title">Signal Transduction and Targeted Therapy, </span><span class="cited-by__entry__volume"><strong>10</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41392-025-02249-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41392-025-02249-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41392-025-02249-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"></ul><span class="cited-by__entry__title">Prevalence of Vision Loss in High-Income Countries and in Eastern and Central Europe in 2020: Magnitude and Temporal Trends, </span><span class="cited-by__entry__series-title">Ophthalmic Epidemiology, </span><span class="cited-by__entry__page-range">(1-14), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/09286586.2025.2486461" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/09286586.2025.2486461</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/09286586.2025.2486461" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zitian Liu, </li><li class="list-inline-item cited-by__entry__author">Yanjing Huang, </li><li class="list-inline-item cited-by__entry__author">Ling Jin, </li><li class="list-inline-item cited-by__entry__author">Caineng Pan, </li><li class="list-inline-item cited-by__entry__author">Xiaotong Han, </li><li class="list-inline-item cited-by__entry__author">Yingfeng Zheng, </li></ul><span class="cited-by__entry__title">Validation of a self-administered Home ETDRS visual acuity testing (H-ETDRS) for self-monitoring vision changes in retinal diseases, </span><span class="cited-by__entry__series-title">British Journal of Ophthalmology, </span><span class="cited-by__entry__page-range">(bjo-2024-326283), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/bjo-2024-326283" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/bjo-2024-326283</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/bjo-2024-326283" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Focke Ziemssen, </li><li class="list-inline-item cited-by__entry__author">Faik Gelisken, </li></ul><span class="cited-by__entry__title">Diabetische Retinopathie und diabetisches Makulaödem, </span><span class="cited-by__entry__series-title">Die Augenheilkunde, </span><span class="cited-by__entry__page-range">(409-425), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/978-3-662-65823-9_44" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/978-3-662-65823-9_44</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/978-3-662-65823-9_44" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhi Yang, </li><li class="list-inline-item cited-by__entry__author">Yizheng Yao, </li><li class="list-inline-item cited-by__entry__author">Xi Chen, </li><li class="list-inline-item cited-by__entry__author">Victoria Madigan, </li><li class="list-inline-item cited-by__entry__author">Shanrui Pu, </li><li class="list-inline-item cited-by__entry__author">Xianqun Fan, </li><li class="list-inline-item cited-by__entry__author">Jun Pu, </li><li class="list-inline-item cited-by__entry__author">Fengfeng Bei, </li></ul><span class="cited-by__entry__title">Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection, </span><span class="cited-by__entry__series-title">Cell Reports Medicine, </span><span class="cited-by__entry__page-range">(102144), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.xcrm.2025.102144" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.xcrm.2025.102144</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.xcrm.2025.102144" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michelle Y. Ko, </li><li class="list-inline-item cited-by__entry__author">Ramin Talebi, </li><li class="list-inline-item cited-by__entry__author">Fei Yu, </li><li class="list-inline-item cited-by__entry__author">Victoria L. Tseng, </li><li class="list-inline-item cited-by__entry__author">Anne L. Coleman, </li><li class="list-inline-item cited-by__entry__author">Hamid Hosseini, </li></ul><span class="cited-by__entry__title">Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab, </span><span class="cited-by__entry__series-title">Clinical Therapeutics, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clinthera.2025.04.010" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clinthera.2025.04.010</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clinthera.2025.04.010" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yang Bai, </li><li class="list-inline-item cited-by__entry__author">Rui Wang, </li><li class="list-inline-item cited-by__entry__author">Can Jin, </li><li class="list-inline-item cited-by__entry__author">Lili Wang, </li><li class="list-inline-item cited-by__entry__author">Yun Tang, </li><li class="list-inline-item cited-by__entry__author">Han Wang, </li><li class="list-inline-item cited-by__entry__author">Kan Ding, </li><li class="list-inline-item cited-by__entry__author">Shanjun Cai, </li></ul><span class="cited-by__entry__title">Impacts of sulfate polysaccharide JCS1S2 on retinal neovascularization in oxygen-induced retinopathy rats, </span><span class="cited-by__entry__series-title">Frontiers in Pharmacology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fphar.2025.1499420" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fphar.2025.1499420</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fphar.2025.1499420" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Francesco Ferrara, </li><li class="list-inline-item cited-by__entry__author">Maurizio Capuozzo, </li><li class="list-inline-item cited-by__entry__author">Roberto Langella, </li><li class="list-inline-item cited-by__entry__author">Giacomo Polito, </li><li class="list-inline-item cited-by__entry__author">Gabriele Bagaglini, </li><li class="list-inline-item cited-by__entry__author">Andrea Zovi, </li></ul><span class="cited-by__entry__title">Consumption and Expenditure on Drugs Used for Macular Degeneration: An Italian Study of Real-World Evidence, </span><span class="cited-by__entry__series-title">SN Comprehensive Clinical Medicine, </span><span class="cited-by__entry__volume"><strong>7</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s42399-025-01836-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s42399-025-01836-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s42399-025-01836-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Catherine M. Lockhart, </li><li class="list-inline-item cited-by__entry__author">Mark R. Barakat, </li><li class="list-inline-item cited-by__entry__author">Jeffrey D. Dunn, </li><li class="list-inline-item cited-by__entry__author">Terry Richardson, </li><li class="list-inline-item cited-by__entry__author">Tori Bratcher, </li><li class="list-inline-item cited-by__entry__author">Estay Greene, </li><li class="list-inline-item cited-by__entry__author">Michael Kobernick, </li><li class="list-inline-item cited-by__entry__author">Doron Schneider, </li><li class="list-inline-item cited-by__entry__author">Jeremy Wigginton, </li></ul><span class="cited-by__entry__title">Transforming retinal disease management through diabetes care, </span><span class="cited-by__entry__series-title">Journal of Managed Care &amp; Specialty Pharmacy, </span><span class="cited-by__entry__volume"><strong>31</strong>, </span><span class="cited-by__entry__issue">4-a Suppl, </span><span class="cited-by__entry__page-range">(S1-S11), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.18553/jmcp.2025.31.4-a.s1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.18553/jmcp.2025.31.4-a.s1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.18553/jmcp.2025.31.4-a.s1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-8%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2204225%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204225" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2204225" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2204225.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f0.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/ca35ae30-b18e-47c3-ac0e-73859ef16b4d/assets/images/large/nejmoa2204225_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f1.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/6868cb6f-1e78-403c-b730-0c246fec4547/assets/images/large/nejmoa2204225_f1.jpg" height="1596" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Time from Randomization to Meeting the Switching Criteria among Eyes Assigned to the Bevacizumab-First Group.</div><div class="notes"><div role="doc-footnote">The criteria for switching to aflibercept monotherapy were persistent center-involved diabetic macular edema (defined as a central subfield thickness above the eligibility threshold), an adequately treated eye (administration of bevacizumab at the previous two consecutive trial visits), no recent improvement in eye condition (no improvement in visual acuity by ≥5 letters and no decrease in central subfield thickness by ≥10% as compared with each of the two preceding visits or between each of the two preceding visits), and suboptimal vision (visual acuity, 20/50 or worse before 24 weeks or 20/32 or worse at 24 weeks or later). Data for eyes that did not meet the criteria for switching to aflibercept therapy were censored at the last completed visit.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f2.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/fad22fbb-1ff0-4d41-b37c-a29580f9e2d4/assets/images/large/nejmoa2204225_f2.jpg" height="3260" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Mean Changes in Visual Acuity and Central Subfield Thickness through 2 Years.</div><div class="notes"><div role="doc-footnote">Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 0 letters (Snellen equivalent, &lt;20/800) to 100 letters (Snellen equivalent, 20/10), with higher scores indicating better visual acuity.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="core-body-ref-r12" href-manipulated="true" aria-label="Reference 12" data-to-manipulate="false">12</a></sup> The data shown are the best-corrected visual acuity in the study eye after protocol-defined refraction (Panel A). Central subfield thickness was measured by optical coherence tomographic scans (Panel B). Measurements made on the Cirrus device were converted to equivalent scores on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="core-body-ref-r11-3" href-manipulated="true" aria-label="Reference 11" data-to-manipulate="false">11</a></sup> In both panels, 𝙸 bars indicate 95% confidence intervals. Data are shown slightly offset at each time point for better visibility.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2204225/asset/e6156d2a-9bca-4687-9ba3-e01b8848776f/assets/images/large/nejmoa2204225_t1.jpg" height="1050" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Criterion</th><th class="xxxx-borders">Definition</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging01 shading">Persistent center-involved diabetic macular edema</td><td class="xxxx-borders hanging01 shading">Central subfield thickness on OCT greater than sex- and device-specific thresholds<a href="#core-t1fn2" role="doc-noteref">†</a></td></tr><tr data-type="row"><td class="xxxx-borders hanging01">Recent treatment of eye</td><td class="xxxx-borders hanging01">Receipt of injection with bevacizumab at the last two trial visits</td></tr><tr data-type="row"><td class="xxxx-borders hanging01 shading">No recent improvement in eye condition</td><td class="xxxx-borders hanging01 shading">Visual-acuity letter score not improved by ≥5 letters and central subfield thickness on OCT not improved by ≥10% as compared with each of the two preceding visits or between each of the two preceding visits</td></tr><tr data-type="row"><td class="xxxx-borders hanging01">Suboptimal vision</td><td class="xxxx-borders hanging01">Approximate Snellen score of 20/50 or worse (≤68 letters) before 24 wk or 20/32 or worse (≤78 letters) at 24 wk or later</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">All four criteria had to be met for eyes to be switched from receiving bevacizumab first to receiving aflibercept therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The thresholds on optical coherence tomography (OCT) were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively, on the Cirrus device (Zeiss).</div></div></div></figcaption></a><figcaption><div class="caption">Criteria for Switch to Aflibercept Therapy at 12 Weeks or Later.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2204225/asset/cfb6a2ed-41f1-4903-86aa-b0e5c84c5e9c/assets/images/large/nejmoa2204225_t2.jpg" height="3344" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Aflibercept-Monotherapy<br>Group<br>(N=158 eyes)</th><th class="txxr-borders">Bevacizumab-First<br>Group<br>(N=154 eyes)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Patient characteristics</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of study eyes</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">116 (73)</td><td class="xxxr-borders shading">112 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">42 (27)</td><td class="xxxr-borders">42 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">60 (55 to 66)</td><td class="xxxr-borders shading">61 (54 to 67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">76 (48)</td><td class="xxxr-borders">74 (48)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">82 (52)</td><td class="xxxr-borders">83 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black or African American</td><td class="xxxx-borders shading">32 (20)</td><td class="xxxr-borders shading">26 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hispanic or Latino</td><td class="xxxx-borders">39 (25)</td><td class="xxxr-borders">41 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Native Hawaiian or other Pacific Islander</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Multiple</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown or not reported</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Type of diabetes — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">7 (4)</td><td class="xxxr-borders shading">8 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">151 (96)</td><td class="xxxr-borders">146 (95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median duration of diabetes (IQR) — yr</td><td class="xxxx-borders shading">15 (9 to 21)</td><td class="xxxr-borders shading">14 (5 to 21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median glycated hemoglobin (IQR) — %<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">8.0 (7.2 to 9.4)</td><td class="xxxr-borders">8.0 (6.8 to 9.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Study eye characteristics</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median visual-acuity letter score (IQR)<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">61 (65 to 54)</td><td class="xxxr-borders">60 (65 to 51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median visual-acuity Snellen equivalent (IQR)</td><td class="xxxx-borders shading">20/63<br>(20/65 to 20/80)</td><td class="xxxr-borders shading">20/63<br>(20/50 to 20/100)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Distribution according to visual acuity — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">68 to 54 letters; Snellen equivalent, 20/50 to 20/80</td><td class="xxxx-borders shading">119 (75)</td><td class="xxxr-borders shading">111 (72)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">53 to 39 letters; Snellen equivalent, 20/100 to 20/160</td><td class="xxxx-borders">28 (18)</td><td class="xxxr-borders">31 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">38 to 24 letters; Snellen equivalent, 20/200 to 20/320</td><td class="xxxx-borders shading">11 (7)</td><td class="xxxr-borders shading">12 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median central subfield thickness on OCT (IQR) — μm<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">478 (401 to 579)</td><td class="xxxr-borders">496 (407 to 628)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Diabetic Retinopathy Severity Scale — no./total no. (%)<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diabetic retinopathy absent or questionable; levels 10, 12, 14, or 15</td><td class="xxxx-borders">0/151</td><td class="xxxr-borders">1/147 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Microaneurysms only; level 20</td><td class="xxxx-borders shading">0/151</td><td class="xxxr-borders shading">2/147 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mild-to-moderate nonproliferative diabetic retinopathy; level 35 or 43</td><td class="xxxx-borders">58/151 (38)</td><td class="xxxr-borders">42/147 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Moderately severe to severe nonproliferative diabetic retinopathy; level 47 or 53</td><td class="xxxx-borders shading">72/151 (48)</td><td class="xxxr-borders shading">79/147 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mild-to-moderate proliferative diabetic retinopathy; level 61 or 65</td><td class="xxxx-borders">15/151 (10)</td><td class="xxxr-borders">16/147 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High-risk proliferative diabetic retinopathy; level 71 or 75</td><td class="xxxx-borders shading">6/151 (4)</td><td class="xxxr-borders shading">7/147 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Previous anti-VEGF treatment for diabetic macular edema — no. (%)</td><td class="xbxx-borders">25 (16)</td><td class="xbxr-borders">29 (19)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Percentages for baseline characteristics are based on numbers of eyes that had undergone randomization rather than on numbers of patients. The 42 patients with two study eyes had one eye in each treatment group. Percentages may not total 100 because of rounding. IQR denotes interquartile range, OCT optical coherence tomography, and VEGF vascular endothelial growth factor.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg"><div class="label">†</div></a><div id="core-t2fn2" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg">Race and ethnic group were reported by the patient on the basis of fixed categories.<sup></sup></a><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="core-body-ref-r10" href-manipulated="true" aria-label="Reference 10" data-to-manipulate="false">10</a></div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Data on the glycated hemoglobin level were unavailable for 10 eyes in each trial group.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The visual-acuity score was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, &lt;20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78+0.95×Cirrus score.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="core-body-ref-r11-1" href-manipulated="true" aria-label="Reference 11" data-to-manipulate="false">11</a></sup> Data were unavailable for two eyes in the aflibercept-monotherapy group; the reading center confirmed the presence of diabetic macular edema in these eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">Severity levels include 12 discrete steps ranging from 10 to 85, with higher levels indicating greater severity.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="core-body-ref-r9-2" href-manipulated="true" aria-label="Reference 9" data-to-manipulate="false">9</a></sup> Level was based on assessment by the reading center. Data were not available for one eye in the bevacizumab-first group. Eyes could not be graded for seven eyes in the aflibercept-monotherapy group and for six eyes in the bevacizumab-first group. Percentages are based on the numbers of eyes with gradable severity of diabetic retinopathy at baseline. No eyes had a severity level of 81 or 85 (indicating advanced proliferative diabetic retinopathy).</div></div></div></figcaption><figcaption><div class="caption">Characteristics of the Patients and Study Eyes at Baseline.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2204225/asset/dc2c2617-5b65-4c8d-8276-eac4fa7368e5/assets/images/large/nejmoa2204225_t3.jpg" height="3438" width="1962" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcomes</th><th class="txxx-borders">Aflibercept-Monotherapy<br>Group<br>(N=132 eyes)</th><th class="txxx-borders">Bevacizumab-First<br>Group<br>(N=128 eyes)</th><th class="txxr-borders">Adjusted Difference<br>(95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Visual-acuity letter score</b><a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Primary outcome: change in visual acuity from baseline over the 2-yr period</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">15.0±8.5</td><td class="xxxx-borders shading">14.0±8.8</td><td class="xxxr-borders shading">0.8 (−0.9 to 2.5)<a href="#core-t3fn3" role="doc-noteref">‡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders">14.8 (9.2 to 20.9)</td><td class="xxxx-borders">13.2 (8.3 to 18.7)</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Visual acuity at 2 yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Letter score</td><td class="xxxx-borders">72±15</td><td class="xxxx-borders">73±13</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean Snellen equivalent</td><td class="xxxx-borders shading">20/40</td><td class="xxxx-borders shading">20/40</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Visual acuity — no. of eyes (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">20/20 or better</td><td class="xxxx-borders shading">29 (22)</td><td class="xxxx-borders shading">28 (22)</td><td class="xxxr-borders shading">−1 (−11 to 8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">20/40 or better</td><td class="xxxx-borders">96 (73)</td><td class="xxxx-borders">95 (74)</td><td class="xxxr-borders">−7 (−19 to 5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">20/200 or worse</td><td class="xxxx-borders shading">6 (5)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (−1 to 7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Mean change from baseline in letter score at 2 yr</td><td class="xxxx-borders">14.7±14.5</td><td class="xxxx-borders">15.9±12.4</td><td class="xxxr-borders">−1.8 (−4.9 to 1.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Improvement in no. of letters — no. of eyes (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">By ≥15 letters</td><td class="xxxx-borders">70 (53)</td><td class="xxxx-borders">74 (58)</td><td class="xxxr-borders">−7 (−21 to 8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">By ≥10 letters</td><td class="xxxx-borders shading">101 (77)</td><td class="xxxx-borders shading">98 (77)</td><td class="xxxr-borders shading">−3 (−13 to 8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Worsening in no. of letters — no. of eyes (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">By ≥10 letters</td><td class="xxxx-borders shading">9 (7)</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">4 (−2 to 9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">By ≥15 letters</td><td class="xxxx-borders">8 (6)</td><td class="xxxx-borders">4 (3)</td><td class="xxxr-borders">3 (−1 to 8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Central subfield thickness on OCT<a href="#core-t3fn4" role="doc-noteref">§</a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">At 2 yr — μm</td><td class="xxxx-borders">315±93</td><td class="xxxx-borders">336±100</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Value below the sex-specific threshold for central-involved diabetic macular edema at 2 yr — no./total no. (%)<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">76/126 (60)</td><td class="xxxx-borders shading">70/127 (55)</td><td class="xxxr-borders shading">4 (−12 to 20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Change from baseline at 2 yr — μm</td><td class="xxxx-borders">−192±143</td><td class="xxxx-borders">−198±160</td><td class="xxxr-borders">−16 (−39 to 7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left"><b>No. of trial visits completed over the 2-yr period<a href="#core-t3fn6" role="doc-noteref">‖</a></b></td><td class="xxxx-borders shading">22.0±3.6</td><td class="xxxx-borders shading">22.5±3.4</td><td class="xxxr-borders shading">−0.5 (−1.5 to 0.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>No. of trial injections administered<a href="#core-t3fn7" role="doc-noteref">**</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">&lt;24 wk</td><td class="xxxx-borders shading">5.7±0.7</td><td class="xxxx-borders shading">5.8±0.5</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">≥24 wk and &lt;1 yr</td><td class="xxxx-borders">3.7±1.8</td><td class="xxxx-borders">4.2±1.8</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">&lt;1 yr</td><td class="xxxx-borders shading">9.3±2.1</td><td class="xxxx-borders shading">10.0±2.0</td><td class="xxxr-borders shading">−0.6 (−1.0 to −0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">≥1 yr and ≤2 yr</td><td class="xxxx-borders">5.3±2.8</td><td class="xxxx-borders">6.1±3.1</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">≤2 yr</td><td class="xbxx-borders shading">14.6±4.1</td><td class="xbxx-borders shading">16.1±4.1</td><td class="xbxr-borders shading">−1.5 (−2.4 to −0.5)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Descriptive statistics (i.e., means with standard deviations, medians with IQRs, and percentages) are reported for eyes in patients who completed the 2-year trial, unless otherwise noted.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, &lt;20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up. Missing data in visual-acuity measurements during follow-up were imputed with the use of multiple imputation for eyes in patients not completing the 2-year visit or when data were otherwise noted as missing, under an assumption that data were missing at random. Outlying values were truncated to ±3 SD from the observed mean at 104 weeks; 14 of 4685 observed visual-acuity values (0.3%) were truncated in the calculation of the AUC. The AUC outcome was calculated after multiple imputation and data truncation were applied, with the use of all observed and imputed data points for each patient. Continuous outcomes were compared between treatment groups with the use of a linear mixed-effects model with a random intercept term (for the correlation between two study eyes in the same patient) and robust variance estimation, with adjustment for baseline visual acuity and number of study eyes. Binary outcomes were compared with the use of logistic regression with a random intercept (for the correlation between two study eyes in the same patient), conditional standardization, and the delta method (for the estimation of risk difference), with adjustment for baseline visual acuity and number of study eyes. Adjustment for baseline visual acuity, number of study eyes, and the correlation between the two study eyes in the same patient were removed from the model only when there was a convergence issue.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">P=0.37.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg"><div class="label">§</div></a><div id="core-t3fn4" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg">Data were available for 126 eyes in the aflibercept-monotherapy group and for 127 eyes in the bevacizumab-first group. Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78+0.95×Cirrus score.<sup></sup></a><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="core-body-ref-r11-2" href-manipulated="true" aria-label="Reference 11" data-to-manipulate="false">11</a> The analysis included only eyes for which baseline data on the central subfield thickness were available. Data on the central subfield thickness at 104 weeks were unavailable for 5 eyes in the aflibercept-monotherapy group and for 1 eye in the bevacizumab-first group. Missing data were imputed with the use of multiple imputation. Comparison of treatment groups was performed with the use of a linear mixed-effects model with a random intercept term for patients and robust variance estimation, with adjustment for baseline central subfield thickness and number of study eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">The OCT thresholds were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus device (Zeiss).<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="core-body-ref-r8-2" href-manipulated="true" data-to-manipulate="false">7,8</a></sup> There was no imputation for this outcome because the threshold values are machine-specific and not Spectralis equivalents, which were imputed. Comparison of treatment groups was performed with the use of logistic regression with a random intercept (for the correlation between two study eyes in the same patient), conditional standardization, and the delta method (for the estimation of risk difference).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">This analysis was limited to patients with one study eye who completed 2 years of follow-up. Data were available for 98 eyes in the aflibercept-monotherapy group and for 94 eyes in the bevacizumab-first group.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t3fn7" role="paragraph" data-to-manipulate="true">The analyses were limited to eyes in patients who completed the visit or any later common visit. All the trial injections were counted, including aflibercept injections that were administered to eyes in the bevacizumab-first group. Estimated differences were adjusted for the number of study eyes in the same patient and the correlation between two study eyes in the same patient. Data were available up to 24 weeks for 148 eyes in the aflibercept-monotherapy group and for 146 eyes in the bevacizumab-first group and up to 1 year for 144 and 142 eyes, respectively.</div></div></div></figcaption><figcaption><div class="caption">Trial Outcomes through 2 Years of Follow-up.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t4"><figure class="table"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2204225/asset/5b9304a0-d736-4a2b-8fb7-9fd27f0d2e89/assets/images/large/nejmoa2204225_t4.jpg" height="2771" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Aflibercept-Monotherapy<br>Group</th><th class="txxx-borders">Bevacizumab-First<br>Group</th><th class="txxx-borders">Patients with<br>Two Study Eyes</th><th class="txxr-borders">P Value</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Systemic adverse events</b><a href="#core-t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">116</td><td class="xxxx-borders">112</td><td class="xxxx-borders">42</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Vascular events defined by APTC criteria — no. (%)<a href="#core-t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonfatal myocardial infarction</td><td class="xxxx-borders">3 (3)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0.52</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonfatal stroke</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxx-borders shading">6 (5)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxr-borders shading">0.56</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Death due to potential vascular cause or unknown cause</td><td class="xxxx-borders">8 (7)</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">2 (5)</td><td class="xxxr-borders">0.14</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">14 (12)</td><td class="xxxx-borders shading">9 (8)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxr-borders shading">0.57</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Prespecified adverse events — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Death from any cause</td><td class="xxxx-borders shading">10 (9)</td><td class="xxxx-borders shading">4 (4)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxr-borders shading">0.28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hospitalization</td><td class="xxxx-borders">56 (48)</td><td class="xxxx-borders">36 (32)</td><td class="xxxx-borders">18 (43)</td><td class="xxxr-borders">0.04<a href="#core-t4fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">60 (52)</td><td class="xxxx-borders shading">40 (36)</td><td class="xxxx-borders shading">18 (43)</td><td class="xxxr-borders shading">0.05</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypertension</td><td class="xxxx-borders">19 (16)</td><td class="xxxx-borders">10 (9)</td><td class="xxxx-borders">11 (26)</td><td class="xxxr-borders">0.02<a href="#core-t4fn5" role="doc-noteref">¶</a></td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Ocular adverse events</b><a href="#core-t4fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of eyes</td><td class="xxxx-borders">158</td><td class="xxxx-borders">154</td><td class="xxxx-borders">—</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Endophthalmitis — no. (%)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.52</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any retinal detachment — no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.08</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Rhegmatogenous retinal detachment</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Traction retinal detachment</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Traumatic cataract — no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Vitreous hemorrhage — no. (%)</td><td class="xxxx-borders">7 (4)</td><td class="xxxx-borders">10 (6)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.53</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Ocular inflammation — no. (%)<a href="#core-t4fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">3 (2)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.53</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Intraocular-pressure elevation — no. (%)<a href="#core-t4fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">15 (9)</td><td class="xxxx-borders">14 (9)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">0.92</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Increase in intraocular pressure ≥10 mm Hg from baseline</td><td class="xxxx-borders shading">10 (6)</td><td class="xxxx-borders shading">6 (4)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intraocular pressure ≥30 mm Hg</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Initiation of medication to lower intraocular pressure that was not in use at baseline</td><td class="xxxx-borders shading">7 (4)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Procedure to treat glaucoma</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Neovascularization of the iris — no. (%)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">0.21</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Neovascular glaucoma — no. (%)</td><td class="xbxx-borders">1 (1)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">—</td><td class="xbxr-borders">0.52</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t4fn1" role="paragraph" data-to-manipulate="true">Unless otherwise specified, data on adverse events were collected at any time during trial follow-up. Some events may have been reported more than once (i.e., at multiple visits). Analyses included patients and study eyes that had at least one adverse event of interest. All the adverse events except intraocular-pressure events were reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t4fn2" role="paragraph" data-to-manipulate="true">The percentages of patients with each systemic adverse event were compared among the three groups with the use of Fisher’s exact test, and global P values are reported. Pairwise comparisons between groups were conducted only if the overall test had a P value of 0.05 or less, with the use of Fisher’s exact test without adjustment for multiple comparisons.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg"><div class="label">‡</div></a><div id="core-t4fn3" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg">Vascular events (those that were definitely or possibly vascular, which included all deaths attributed to cardiac, cerebral, hemorrhagic, embolic, other vascular, or unknown causes) were defined according to the criteria of the Antiplatelet Trialists’ Collaboration (APTC).<sup></sup></a><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="core-body-ref-r13" href-manipulated="true" aria-label="Reference 13" data-to-manipulate="false">13</a></div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t4fn4" role="paragraph" data-to-manipulate="true">P=0.02 for the comparison of the aflibercept-monotherapy group with the bevacizumab-first group, 0.59 for the comparison of the aflibercept-monotherapy group with the group of patients with two study eyes, and 0.26 for the comparison of the bevacizumab-first group with the group of patients with two study eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t4fn5" role="paragraph" data-to-manipulate="true">P=0.11 for the comparison of the aflibercept-monotherapy group with the bevacizumab-first group, 0.17 for the comparison of the aflibercept-monotherapy group with the group of patients with two study eyes, and 0.009 for the comparison of the bevacizumab-first group with the group of patients with two study eyes.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t4fn6" role="paragraph" data-to-manipulate="true">The percentages of eyes that had each outcome were compared between treatment groups with the use of Barnard’s unconditional exact test, with the number of eyes in each treatment group as a fixed margin.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t4fn7" role="paragraph" data-to-manipulate="true">Inflammation included the presence of inflammatory cells or flare in the anterior chamber, pseudohypopyon, chorioretinitis, choroiditis, pseudoendophthalmitis, iritis, uveitis, and the presence of vitreal cells.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t4fn8" role="paragraph" data-to-manipulate="true">Intraocular-pressure elevation was defined as an increase in intraocular pressure of 10 mm Hg or more from baseline at any visit, an intraocular pressure of 30 mm Hg or more at any visit, the initiation of medication to lower intraocular pressure that was not in use at baseline, or procedure to treat glaucoma.</div></div></div></figcaption><figcaption><div class="caption">Systemic and Ocular Adverse Events of Special Interest through 2 Years of Follow-up.<a href="#core-t4fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t4"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204225_t4.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2204225</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern. <em>Ophthalmology</em> 2020;127(1):P66-P145.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2019.09.025" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31757498/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000503224300010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diabetic+retinopathy+preferred+practice+pattern.&amp;publication_year=2020&amp;journal=Ophthalmology&amp;pages=P66-P145&amp;doi=10.1016%2Fj.ophtha.2019.09.025&amp;pmid=31757498" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cause of vision loss in working-age adults. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] factor (anti-VEGF) agents into the eye. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. <em>Eye Vis (Lond)</em> 2015;2:17-17.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s40662-015-0026-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26605370/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457289400017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiology+of+diabetic+retinopathy%2C+diabetic+macular+edema+and+related+vision+loss.&amp;publication_year=2015&amp;journal=Eye+Vis+%28Lond%29&amp;pages=17-17&amp;doi=10.1186%2Fs40662-015-0026-2&amp;pmid=26605370" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. <em>Ophthalmology</em> 2012;119:789-801.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2011.12.039" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22330964/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302355400018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ranibizumab+for+diabetic+macular+edema%3A+results+from+2+phase+III+randomized+trials%3A+RISE+and+RIDE.&amp;publication_year=2012&amp;journal=Ophthalmology&amp;pages=789-801&amp;doi=10.1016%2Fj.ophtha.2011.12.039&amp;pmid=22330964" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. <em>Ophthalmology</em> 2015;122:2044-2052.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2015.06.017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26198808/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363491500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravitreal+aflibercept+for+diabetic+macular+edema%3A+100-week+results+from+the+VISTA+and+VIVID+studies.&amp;publication_year=2015&amp;journal=Ophthalmology&amp;pages=2044-2052&amp;doi=10.1016%2Fj.ophtha.2015.06.017&amp;pmid=26198808" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. <em>Ophthalmology</em> 2016;123:1351-1359.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2016.02.022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26935357/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000376506400033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Aflibercept%2C+bevacizumab%2C+or+ranibizumab+for+diabetic+macular+edema%3A+two-year+results+from+a+comparative+effectiveness+randomized+clinical+trial.&amp;publication_year=2016&amp;journal=Ophthalmology&amp;pages=1351-1359&amp;doi=10.1016%2Fj.ophtha.2016.02.022&amp;pmid=26935357" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] are effective in improving visual acuity. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] baseline visual acuity of 20/40 or better, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] through 1 year than ranibizumab therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] with adjustment for baseline visual acuity, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] than with bevacizumab monotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] as compared with bevacizumab monotherapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Sachs RE, Kyle MA. Step therapy’s balancing act — protecting patients while addressing high drug prices. <em>N Engl J Med</em> 2022;386:901-904.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2204225&amp;key=10.1056%2FNEJMp2117582&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35245014/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000764894200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Step+therapy%E2%80%99s+balancing+act+%E2%80%94+protecting+patients+while+addressing+high+drug+prices.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=901-904&amp;doi=10.1056%2FNEJMp2117582&amp;pmid=35245014" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Chalam KV, Bressler SB, Edwards AR, et al. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. <em>Invest Ophthalmol Vis Sci</em> 2012;53:8154-8161.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1167/iovs.12-10290" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23132803/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000313056000033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Retinal+thickness+in+people+with+diabetes+and+minimal+or+no+diabetic+retinopathy%3A+Heidelberg+Spectralis+optical+coherence+tomography.&amp;publication_year=2012&amp;journal=Invest+Ophthalmol+Vis+Sci&amp;pages=8154-8161&amp;doi=10.1167%2Fiovs.12-10290&amp;pmid=23132803" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on optical coherence tomography (OCT). </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r7-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] respectively on the Cirrus device (Zeiss). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. <em>JAMA</em> 2015;314:2137-2146.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2015.15217" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26565927/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365351900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Panretinal+photocoagulation+vs+intravitreous+ranibizumab+for+proliferative+diabetic+retinopathy%3A+a+randomized+clinical+trial.&amp;publication_year=2015&amp;journal=JAMA&amp;pages=2137-2146&amp;doi=10.1001%2Fjama.2015.15217&amp;pmid=26565927" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] on optical coherence tomography (OCT). </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r8-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] respectively on the Cirrus device (Zeiss). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Grading diabetic retinopathy from stereoscopic color fundus photographs — an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. <em>Ophthalmology</em> 1991;98:786-806.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0161-6420(13)38012-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2062513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1991FL41900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Grading+diabetic+retinopathy+from+stereoscopic+color+fundus+photographs+%E2%80%94+an+extension+of+the+modified+Airlie+House+classification.+ETDRS+report+number+10.+Early+Treatment+Diabetic+Retinopathy+Study+Research+Group.&amp;publication_year=1991&amp;journal=Ophthalmology&amp;pages=786-806&amp;doi=10.1016%2FS0161-6420%2813%2938012-9&amp;pmid=2062513" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] higher levels indicating greater severity. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r9-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] higher levels indicating greater severity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">National Institutes of Health. Racial and ethnic categories and definitions for NIH diversity programs and for other reporting purposes. April 8, 2015 (<a href="https://grants.nih.gov/grants/guide/notice-files/not-od-15-089.html">https://grants.nih.gov/grants/guide/notice-files/not-od-15-089.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Racial+and+ethnic+categories+and+definitions+for+NIH+diversity+programs+and+for+other+reporting+purposes.&amp;publication_year=2015" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Sun JK, Josic K, Melia M, et al. Conversion of central subfield thickness measurements of diabetic macular edema across Cirrus and Spectralis optical coherence tomography instruments. <em>Transl Vis Sci Technol</em> 2021;10:34-34.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1167/tvst.10.14.34" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34967834/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Conversion+of+central+subfield+thickness+measurements+of+diabetic+macular+edema+across+Cirrus+and+Spectralis+optical+coherence+tomography+instruments.&amp;publication_year=2021&amp;journal=Transl+Vis+Sci+Technol&amp;pages=34-34&amp;doi=10.1167%2Ftvst.10.14.34&amp;pmid=34967834" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation open-in-viewer" href="#t2" role="menuitem" data-target="#fv-body-ref-r11-1"><i aria-hidden="true" class="icon-return"></i><span>a [...] Spectralis score = 40.78+0.95×Cirrus score. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t3" role="menuitem" data-target="#fv-body-ref-r11-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] Spectralis score = 40.78+0.95×Cirrus score. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f2" role="menuitem" data-target="#fv-body-ref-r11-3"><i aria-hidden="true" class="icon-return"></i><span>c [...] score = 40.78 + 0.95 × Cirrus score. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. <em>Am J Ophthalmol</em> 2003;135:194-205.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0002-9394(02)01825-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12566024/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000180709400011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+computerized+method+of+visual+acuity+testing%3A+adaptation+of+the+early+treatment+of+diabetic+retinopathy+study+testing+protocol.&amp;publication_year=2003&amp;journal=Am+J+Ophthalmol&amp;pages=194-205&amp;doi=10.1016%2FS0002-9394%2802%2901825-1&amp;pmid=12566024" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. <em>BMJ</em> 1994;308:81-106.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.308.6921.81" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8298418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994MR17300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Collaborative+overview+of+randomised+trials+of+antiplatelet+therapy.+I.+Prevention+of+death%2C+myocardial+infarction%2C+and+stroke+by+prolonged+antiplatelet+therapy+in+various+categories+of+patients.&amp;publication_year=1994&amp;journal=BMJ&amp;pages=81-106&amp;doi=10.1136%2Fbmj.308.6921.81&amp;pmid=8298418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Centers for Medicare and Medicaid Services. 2022 ASP drug pricing files. 2022 (<a href="https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files">https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2022-asp-drug-pricing-files</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2022+ASP+drug+pricing+files.&amp;publication_year=2022" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Centers for Medicare and Medicaid Services. Medicare Advantage prior authorization and step therapy for Part B drugs. August 7, 2018 (<a href="https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-prior-authorization-and-step-therapy-part-b-drugs">https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-prior-authorization-and-step-therapy-part-b-drugs</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Medicare+Advantage+prior+authorization+and+step+therapy+for+Part+B+drugs.&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. <em>N Engl J Med</em> 2015;372:1193-1203.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2204225&amp;key=10.1056%2FNEJMoa1414264&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25692915/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000351585900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Aflibercept%2C+bevacizumab%2C+or+ranibizumab+for+diabetic+macular+edema.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1193-1203&amp;doi=10.1056%2FNEJMoa1414264&amp;pmid=25692915" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Heier JS, Korobelnik J-F, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. <em>Ophthalmology</em> 2016;123:2376-2385.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ophtha.2016.07.032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27651226/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000389509500022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Intravitreal+aflibercept+for+diabetic+macular+edema%3A+148-week+results+from+the+VISTA+and+VIVID+studies.&amp;publication_year=2016&amp;journal=Ophthalmology&amp;pages=2376-2385&amp;doi=10.1016%2Fj.ophtha.2016.07.032&amp;pmid=27651226" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 14, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2208454" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Evidence for Step Therapy in Diabetic Macular Edema</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.C. Musch and E.Y. Chew</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Everett, Massachusetts</span></div><div><span>Nephrology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886825/nephrologist/?query=fjwp&amp;rid=1038">Nephrologist</a></div></div><div class="nejm-widget_item"><div><span> Connecticut</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/876613/internal-medicine-physician/?query=fjwp&amp;rid=165114">Internal Medicine Physician</a></div></div><div class="nejm-widget_item"><div><span> Oregon</span></div><div><span>Dermatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890829/portland-oregon-area-group-adding-mohs-dermatologist-partnership/?query=fjwf&amp;rid=5127">Portland, Oregon Area Group Adding Mohs/Dermatologist - Partnership</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/866866/emergency-radiologist/?query=fjwp&amp;rid=3059">Emergency Radiologist</a></div></div><div class="nejm-widget_item"><div><span> Bay Shore, New York</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/808182/director-of-pediatric-hospital-medicine-ssuh-suffolk-county-ny/?query=fjwp&amp;rid=3059">Director of Pediatric Hospital Medicine, SSUH - Suffolk County, NY</a></div></div><div class="nejm-widget_item"><div><span> Mount Vernon, Illinois</span></div><div><span>Radiation Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888886/bc-radiation-oncology-need-outside-of-st-louis-in-southern-il/?query=fjwf&amp;rid=196467">BC Radiation Oncology need outside of St. Louis in Southern IL</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2204225&amp;pubId=41284678&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6e50f3229f214-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6e50f3229f214-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6e50f3229f214-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$956057055$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$956057055$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$956057055$--></div></div><div class="mlt-body"><!--?lit$956057055$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$956057055$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$956057055$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$956057055$-->Apr 23, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra1909637?query=recirc_Semantic" target="_self">Evaluation and Care of Patients with Diabetic Retinopathy</a></div><div class="mlt-article-authors"><!--?lit$956057055$-->L.M. Jampol, A.R. Glassman, and J. Sun</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$956057055$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$956057055$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$956057055$-->Jul 30, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2018871?query=recirc_Semantic" target="_self">Evaluation and Care of Patients with Diabetic Retinopathy</a></div><div class="mlt-article-authors"><!--?lit$956057055$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$956057055$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$956057055$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$956057055$-->Apr 22, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400009?query=recirc_Semantic" target="_self">Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema</a></div><div class="mlt-article-authors"><!--?lit$956057055$-->S. Klier and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-catalyst" href="https://catalyst.nejm.org/browse/nejm-article-type/article?query=recirc_Semantic" target="_self"><!--?lit$956057055$-->Article</a> <span class="mlt-article-site-label"><!--?lit$956057055$-->NEJM Catalyst</span> <span class="mlt-article-pubdate"><!--?lit$956057055$-->Apr 20, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0375?query=recirc_Semantic" target="_self">Targeted Management of Excess Specialty Spending: The Case of Biologics for Retinal Disease</a></div><div class="mlt-article-authors"><!--?lit$956057055$-->H. Moon and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/editorial?query=recirc_Semantic" target="_self"><!--?lit$956057055$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$956057055$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$956057055$-->Apr 22, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDe2500004?query=recirc_Semantic" target="_self">Foselutoclax (UBX1325) for Diabetic Macular Edema — A Potential Novel Therapy?</a></div><div class="mlt-article-authors"><!--?lit$956057055$-->E.Y. Chew</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2204225?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2204225" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2204225.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2204225"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2207323" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2201904" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f0.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/ca35ae30-b18e-47c3-ac0e-73859ef16b4d/assets/images/large/nejmoa2204225_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f1.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/6868cb6f-1e78-403c-b730-0c246fec4547/assets/images/large/nejmoa2204225_f1.jpg" height="1596" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Time from Randomization to Meeting the Switching Criteria among Eyes Assigned to the Bevacizumab-First Group.</div><div class="notes"><div role="doc-footnote">The criteria for switching to aflibercept monotherapy were persistent center-involved diabetic macular edema (defined as a central subfield thickness above the eligibility threshold), an adequately treated eye (administration of bevacizumab at the previous two consecutive trial visits), no recent improvement in eye condition (no improvement in visual acuity by ≥5 letters and no decrease in central subfield thickness by ≥10% as compared with each of the two preceding visits or between each of the two preceding visits), and suboptimal vision (visual acuity, 20/50 or worse before 24 weeks or 20/32 or worse at 24 weeks or later). Data for eyes that did not meet the criteria for switching to aflibercept therapy were censored at the last completed visit.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204225_f2.jpg"><img src="/cms/10.1056/NEJMoa2204225/asset/fad22fbb-1ff0-4d41-b37c-a29580f9e2d4/assets/images/large/nejmoa2204225_f2.jpg" height="3260" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Mean Changes in Visual Acuity and Central Subfield Thickness through 2 Years.</div><div class="notes"><div role="doc-footnote">Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 0 letters (Snellen equivalent, &lt;20/800) to 100 letters (Snellen equivalent, 20/10), with higher scores indicating better visual acuity.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="fv-body-ref-r12" href-manipulated="true" aria-label="Reference 12" data-to-manipulate="false">12</a></sup> The data shown are the best-corrected visual acuity in the study eye after protocol-defined refraction (Panel A). Central subfield thickness was measured by optical coherence tomographic scans (Panel B). Measurements made on the Cirrus device were converted to equivalent scores on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="fv-body-ref-r11-3" href-manipulated="true" aria-label="Reference 11" data-to-manipulate="false">11</a></sup> In both panels, 𝙸 bars indicate 95% confidence intervals. Data are shown slightly offset at each time point for better visibility.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Criteria for Switch to Aflibercept Therapy at 12 Weeks or Later.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients and Study Eyes at Baseline.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Trial Outcomes through 2 Years of Follow-up.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t4" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 4</div><div class="fv__item__description"><figcaption><div class="caption">Systemic and Ocular Adverse Events of Special Interest through 2 Years of Follow-up.<a href="#fv-t4fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/8" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 8</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 25, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2201302" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.S. Smolen and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 25, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2207323" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.P. Thornhill and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 25, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2201904" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L. Steinman and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2204225%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2204225&amp;pubId=41284678&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2204225%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2204225&amp;pubId=41284678&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06394299502371115" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6e50f3229f214-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6e50f3229f214-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6e50f3229f214-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6e50f3229f214-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6e50f3229f214-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6e50f3229f214-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6e50f3229f214-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6e50f3229f214-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6e50f3229f214-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6e50f3229f214-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6e50f2b67f214',t:'MTc0OTUzNzgxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6e50f2b67f214&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><foe-cjcuolgknnqn></foe-cjcuolgknnqn><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2204225?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-transactionid="6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" id="captureIFrame_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" target="captureIFrame_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="capture_screen"><input id="capture_signIn_js_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="js_version"><input id="capture_signIn_transactionId_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" type="hidden" class="capture_transactionId_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="capture_transactionId"><input id="capture_signIn_form_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="form"><input id="capture_signIn_flow_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="flow"><input id="capture_signIn_client_id_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="client_id"><input id="capture_signIn_redirect_uri_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="redirect_uri"><input id="capture_signIn_response_type_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="response_type"><input id="capture_signIn_flow_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="flow_version"><input id="capture_signIn_settings_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="settings_version"><input id="capture_signIn_locale_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="locale"><input id="capture_signIn_recaptcha_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_6srjpyq0pak4246xaejc089wn3qb3e51yd80iddc" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>